<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Rep</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407658</article-id><article-id pub-id-type="pmc">PMC12101273</article-id>
<article-id pub-id-type="doi">10.3390/idr17030056</article-id><article-id pub-id-type="publisher-id">idr-17-00056</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Long COVID: A Systematic Review of Preventive Strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5746-395X</contrib-id><name><surname>Park</surname><given-names>Sun O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nanda</surname><given-names>Neha</given-names></name><xref rid="c1-idr-17-00056" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Petrosillo</surname><given-names>Nicola</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-idr-17-00056">Division of Infectious Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA</aff><author-notes><corresp id="c1-idr-17-00056"><label>*</label>Correspondence: <email>neha.nanda@med.usc.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>56</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>02</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, long COVID (LC) has become a significant global health burden. While knowledge about LC is accumulating, studies on its prevention are still lacking. <bold>Methods:</bold> We conducted a systematic review following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to investigate prevention options for LC. We identified fifteen articles on vaccines, seven on antivirals, and six on other interventions after searching for articles in the PubMed/MEDLINE database using the MeSH terms. <bold>Results:</bold> Most vaccine-related studies demonstrated a protective effect of COVID-19 vaccines against developing LC. Our review found an equivocal effect of antivirals, while metformin had a protective effect in outpatients and corticosteroids were protective in hospitalized patients against LC. Conversely, COVID-19 convalescent plasma and multiple micronutrient supplement did not confer any protection against LC. <bold>Conclusions:</bold> COVID-19 vaccination is vital as it not only prevents COVID-19 but also reduces the severity of illness and may help prevent LC. Further studies are warranted to shed light on preventive strategies for long COVID.</p></abstract><kwd-group><kwd>long COVID</kwd><kwd>post-acute sequelae of COVID-19 (PASC)</kwd><kwd>post-acute COVID-19 syndrome (PACS)</kwd><kwd>post-COVID-19 conditions (PCCs)</kwd><kwd>COVID-19</kwd><kwd>prevention</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-idr-17-00056"><title>1. Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, was first identified in December 2019 in the city of Wuhan, China. COVID-19 rapidly spread worldwide, resulting in a major global pandemic [<xref rid="B1-idr-17-00056" ref-type="bibr">1</xref>] that has caused over 1 million deaths in the United States (US) and 7 million deaths globally [<xref rid="B2-idr-17-00056" ref-type="bibr">2</xref>]. Moreover, a subset of individuals infected with SARS-CoV-2 may experience persistent somatic symptoms, a condition known as long COVID (LC), also referred to as Post-Acute Sequelae of COVID-19 (PASC), Post-Acute COVID-19 Syndrome (PACS), or Post-COVID-19 Conditions (PCCs) [<xref rid="B2-idr-17-00056" ref-type="bibr">2</xref>,<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>].</p><p>LC is a complex and heterogeneous condition lacking specific biomarkers, which has posed challenges in accurately estimating its burden and developing prevention and management strategies [<xref rid="B2-idr-17-00056" ref-type="bibr">2</xref>,<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>]. While definitions of LC vary, international scientific agencies agree on a timeline of symptom persistence, defining it as symptoms lasting 3 months or longer. The World Health Organization (WHO) defines LC as the continuation or development of new symptoms&#x02014;including over 200 different symptoms that can impact everyday functioning&#x02014;occurring 3 months after the initial SARS-CoV-2 infection, with no other explanation [<xref rid="B4-idr-17-00056" ref-type="bibr">4</xref>]. Similarly, the US National Academic Sciences Engineering Medicine (NASEM) described LC as a SARS-CoV-2 infection-associated condition persisting beyond 3 months, presenting as a continuous, relapsing and remitting, or progressive disease state affecting one or more organ systems [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>]. The Centers for Disease Control and Prevention (CDC) updated its definition to reflect symptoms persisting for at least 3 months after infection.</p><p>Based on data collected between 2020 and 2021 from 22 countries, approximately 6.2% of individuals of all ages experienced at least one of three LC symptom clusters&#x02014;persistent fatigue with body pain or mood swings, cognitive problems, or ongoing respiratory issues&#x02014;3 months after SARS-CoV-2 infection [<xref rid="B5-idr-17-00056" ref-type="bibr">5</xref>]. LC negatively impacts quality of life, leading to significant health and economic strain on individuals and health care systems [<xref rid="B6-idr-17-00056" ref-type="bibr">6</xref>].</p><p>Studies demonstrating the impact of vaccines or antivirals on LC are accumulating; however, systematic reviews synthesizing these outcomes are scarce. A recent meta-analysis, in which LC was defined as symptoms lasting 30 days or longer, found that antiviral treatment during acute COVID-19 significantly reduced the risk of LC; in contrast, corticosteroids and monoclonal antibodies did not show protective effects [<xref rid="B7-idr-17-00056" ref-type="bibr">7</xref>]. Another meta-analysis assessing vaccines&#x02019; effect found that receiving a primary vaccine series prior to COVID-19 was associated with reduced odds of developing LC, while one dose or three does did not [<xref rid="B8-idr-17-00056" ref-type="bibr">8</xref>]. A meta-analysis of heterogeneous studies may lead to erroneous conclusions. We aim to shed light on interventions for the prevention of LC. Our objectives are to (1) review the pathogenic mechanisms and risk factors of LC and (2) systematically review interventions, particularly vaccines and antivirals, for LC prevention using the definition of LC as symptoms persisting for 3 months or longer after SARS-CoV-2 infection, aligning with the definitions of the WHO, NASEM, and CDC.</p></sec><sec id="sec2-idr-17-00056"><title>2. The Pathogenic Mechanism of Long COVID</title><p>Long COVID can affect multiple organs, including those in the respiratory (e.g., cough or shortness of breath), cardiovascular (e.g., chest pain or palpitations), neurological (e.g., headache, loss of taste or smell, anxiety, cognitive impairment, fatigue, or insomnia), gastrointestinal (e.g., nausea, vomiting, diarrhea, abdominal pain, or loss of appetite), endocrine (e.g., thyroid dysfunction or new onset diabetes), musculoskeletal (e.g., myalgia or joint pain), reproductive (e.g., erectile dysfunction or irregular menstruation), and immune systems (e.g., autoimmunity or mast cell activation syndrome), leading to a wide variety of symptoms [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>,<xref rid="B9-idr-17-00056" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00056" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00056" ref-type="bibr">11</xref>]. Long-lasting symptoms after acute infection with SARS-CoV-2 are not unique; a variety of chronic conditions triggered by other infectious agents have been well described [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>]. Examples include long-lasting symptoms caused by neurotrophic herpesviruses, enteroviruses, Ebola virus, MERS viruses, <italic toggle="yes">Borrelia</italic> spp. (implicating pathogen for Lyme disease), and chronic fatigue syndrome caused by <italic toggle="yes">Coxiella burnetii</italic> (implicating pathogen for Q fever) [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>]. Moreover, there are many similarities in the pathophysiology and biological abnormalities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and LC, including nervous system dysfunction, cardiovascular abnormalities, immune system dysregulation, metabolic alterations, and gut microbiome alterations, suggesting potential overlapping mechanisms [<xref rid="B12-idr-17-00056" ref-type="bibr">12</xref>]. Insights from one condition may help understand the other [<xref rid="B12-idr-17-00056" ref-type="bibr">12</xref>]. At this time, the mechanisms of LC pathogenesis are not fully elucidated and can vary between individuals [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>] and due to other external factors. For example, the incidence of LC may be less common with Omicron variants compared to earlier variants [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>]. Interestingly, compared to the pre-Delta and Delta eras combined, gastrointestinal, metabolic, and musculoskeletal disorders have increased during the Omicron era, while symptoms related to other systems like the respiratory and neurological systems have decreased over time. This indicates a shift in the phenotypic features of LC, which is likely influenced by the evolving virus and vaccination [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>].</p><p>The key mechanisms hypothesized for LC pathogenesis include persistent viral reservoirs, immune dysregulation and inflammatory responses, autoimmunity, reactivation of latent herpesviruses, microvascular and endothelial dysfunction, nervous system dysfunction, and microbiota dysbiosis.</p><p>Persistent viral reservoirs: LC consists of a broad range of symptoms lasting beyond 3 months after infection regardless of the presence of viral particles. However, compared to individuals who do not develop LC, LC patients are more likely to have persistent viral RNA or protein in their tissues or blood, potentially establishing a reservoir [<xref rid="B14-idr-17-00056" ref-type="bibr">14</xref>,<xref rid="B15-idr-17-00056" ref-type="bibr">15</xref>,<xref rid="B16-idr-17-00056" ref-type="bibr">16</xref>]. In one of the studies, autopsies on 44 patients were conducted, and in 11 patients, they detected the replication of SARS-CoV-2 in multiple anatomic sites, including the brain [<xref rid="B15-idr-17-00056" ref-type="bibr">15</xref>]. Additionally, SARS-CoV-2 proteins or RNA in specific tissues may drive LC pathogenesis, such as chronic inflammation, immune dysregulation, latent pathogens reactivation, vascular abnormalities, and microbiome dysbiosis, leading to persistent symptoms [<xref rid="B14-idr-17-00056" ref-type="bibr">14</xref>].</p><p>Immune dysregulation and inflammatory responses: Insufficient SARS-CoV-2 antibody production and altered T cell responses during acute COVID-19 may be predictive of LC [<xref rid="B9-idr-17-00056" ref-type="bibr">9</xref>,<xref rid="B17-idr-17-00056" ref-type="bibr">17</xref>,<xref rid="B18-idr-17-00056" ref-type="bibr">18</xref>]. LC patients demonstrate persistently elevated inflammatory cytokines, such as IFN- &#x003b2;, IFN- &#x003bb;1, IL-1&#x003b2;, IL-6, TNF-&#x003b1;, IP10, and CCL11, with some remaining elevated even months after COVID-19 infection [<xref rid="B18-idr-17-00056" ref-type="bibr">18</xref>,<xref rid="B19-idr-17-00056" ref-type="bibr">19</xref>]. In addition, LC patients exhibit decreased CD4+ and CD8+ effector memory cells, highly activated innate immune cells, and a loss of na&#x000ef;ve T and B cells, possibly reflecting the persistent conversion of na&#x000ef;ve T cells into activated phenotypes driven by bystander activation or prolonged antigen presentation due to underlying inflammation [<xref rid="B19-idr-17-00056" ref-type="bibr">19</xref>]. The increased expression of T cell exhaustion markers (PD-1 and TIM-3) and activation markers (CD38 and HLA-DR), together with the above immune dysregulation, may contribute to persistent symptoms in LC patients by impairing viral clearance and promoting chronic inflammation [<xref rid="B19-idr-17-00056" ref-type="bibr">19</xref>]. The production of autoantibodies (autoAbs), such as anti-nuclear Abs (Ro/SS-A, La/SS-B, U1-snRNP, Jo-1, and P1) and anti-IFN-a2, is common in LC patients, which is negatively correlated with the production of anti-SARS-CoV-2 antibodies [<xref rid="B20-idr-17-00056" ref-type="bibr">20</xref>]. Furthermore, some individuals may already have autoAbs even before COVID-19 infection, and COVID-19 may unmask subclinical autoimmune conditions, leading to persistent inflammation and immune changes that contribute to LC [<xref rid="B20-idr-17-00056" ref-type="bibr">20</xref>]. Additionally, immune dysregulation promoted by SARS-CoV-2 can reactivate latent herpesviruses such as EBV and CMV, potentially worsening LC symptoms [<xref rid="B9-idr-17-00056" ref-type="bibr">9</xref>,<xref rid="B11-idr-17-00056" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00056" ref-type="bibr">12</xref>,<xref rid="B21-idr-17-00056" ref-type="bibr">21</xref>].</p><p>Microvascular and endothelial dysfunction: SARS-CoV-2 can impair microcirculation and endothelial function, leading to reduced oxygen delivery, clotting, and subsequent multiorgan damages [<xref rid="B9-idr-17-00056" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00056" ref-type="bibr">10</xref>]. Persistent microclots containing inflammatory molecules, such as &#x003b1;2-antiplasmin and amyloid A, have been observed in LC patients, potentially contributing to persistent symptoms [<xref rid="B22-idr-17-00056" ref-type="bibr">22</xref>].</p><p>Nervous system dysfunction: Neurological symptoms in LC patients may result from the direct neuroinvasion of SARS-CoV-2 through crossing the blood&#x02013;brain barrier, accessing neural pathways, or from neuroinflammation triggered by systemic inflammatory responses caused by immune cell activation and cytokine release [<xref rid="B9-idr-17-00056" ref-type="bibr">9</xref>,<xref rid="B23-idr-17-00056" ref-type="bibr">23</xref>,<xref rid="B24-idr-17-00056" ref-type="bibr">24</xref>,<xref rid="B25-idr-17-00056" ref-type="bibr">25</xref>]. Additionally, impaired peripheral vasoconstriction and reduced tissue oxygen supply may contribute to neurological dysfunction [<xref rid="B24-idr-17-00056" ref-type="bibr">24</xref>,<xref rid="B25-idr-17-00056" ref-type="bibr">25</xref>]. Key characteristics of LC include neurological and cognitive dysfunction (&#x0201c;brain fog&#x0201d;), such as fatigue, headache, memory loss, cognitive impairment, sensorimotor dysfunction, altered smell and taste, and autonomic dysfunction such as temperature dysregulation, postural orthostatic tachycardia syndrome (POTS), and orthostatic hypotension [<xref rid="B9-idr-17-00056" ref-type="bibr">9</xref>,<xref rid="B12-idr-17-00056" ref-type="bibr">12</xref>,<xref rid="B25-idr-17-00056" ref-type="bibr">25</xref>].</p><p>Microbiota dysbiosis: SARS-CoV-2 can disrupt the gut microbiome, resulting in persistent gastrointestinal (GI) symptoms and even respiratory and neurological symptoms [<xref rid="B25-idr-17-00056" ref-type="bibr">25</xref>,<xref rid="B26-idr-17-00056" ref-type="bibr">26</xref>,<xref rid="B27-idr-17-00056" ref-type="bibr">27</xref>,<xref rid="B28-idr-17-00056" ref-type="bibr">28</xref>]. The restoration of healthy microbiota could potentially reverse chronic symptoms in LC patients [<xref rid="B29-idr-17-00056" ref-type="bibr">29</xref>].</p></sec><sec id="sec3-idr-17-00056"><title>3. Risk Factors for Long COVID</title><p>Multiple studies have shown that females are more likely than males to develop LC [<xref rid="B30-idr-17-00056" ref-type="bibr">30</xref>,<xref rid="B31-idr-17-00056" ref-type="bibr">31</xref>,<xref rid="B32-idr-17-00056" ref-type="bibr">32</xref>,<xref rid="B33-idr-17-00056" ref-type="bibr">33</xref>]. A prospective cohort study found that the female sex was associated with a 3-fold higher risk of developing LC [<xref rid="B31-idr-17-00056" ref-type="bibr">31</xref>]. A multicenter cohort study also described that the number of LC symptoms was significantly higher in females than in males, with means of 2.25 and 1.5, respectively [<xref rid="B32-idr-17-00056" ref-type="bibr">32</xref>]. Biological factors, such as higher estrogen levels in females, might contribute to the development of LC, as estrogen can upregulate angiotensin-converting enzyme 2 (ACE2), a receptor used by SARS-CoV-2 to enter host cells [<xref rid="B10-idr-17-00056" ref-type="bibr">10</xref>,<xref rid="B34-idr-17-00056" ref-type="bibr">34</xref>], although the impact of ACE2 on LC remains unclear [<xref rid="B34-idr-17-00056" ref-type="bibr">34</xref>]. Behavioral differences, such as females being more attentive to bodily distress and more likely to seek medical care, may also contribute to the higher rate of LC in females [<xref rid="B31-idr-17-00056" ref-type="bibr">31</xref>,<xref rid="B32-idr-17-00056" ref-type="bibr">32</xref>].</p><p>Another risk factor for LC is the severity of the illness during the acute phase. Patients with more severe symptoms&#x02014;such as being hospitalized, requiring analgesics, or needing additional treatments, are at a higher risk of developing LC [<xref rid="B35-idr-17-00056" ref-type="bibr">35</xref>,<xref rid="B36-idr-17-00056" ref-type="bibr">36</xref>,<xref rid="B37-idr-17-00056" ref-type="bibr">37</xref>]. For example, a population-based cohort study with a total of 1459 patients found that the prevalence of LC was higher in hospitalized patients than in non-hospitalized patients, with prevalence rates of 72.6% and 46.2%, respectively [<xref rid="B35-idr-17-00056" ref-type="bibr">35</xref>]. Additionally, a cohort study by Guzman-Esquivel et al. demonstrated a positive relationship between LC and factors such as hospitalization and antibiotic use [<xref rid="B36-idr-17-00056" ref-type="bibr">36</xref>].</p><p>Middle age or advanced age is associated with an increased risk of developing LC [<xref rid="B37-idr-17-00056" ref-type="bibr">37</xref>,<xref rid="B38-idr-17-00056" ref-type="bibr">38</xref>]. Additionally, overweight and obesity have been linked to a higher risk of developing LC [<xref rid="B37-idr-17-00056" ref-type="bibr">37</xref>,<xref rid="B39-idr-17-00056" ref-type="bibr">39</xref>]. A high overall burden of comorbidities, as well as pulmonary conditions such as asthma, chronic obstructive pulmonary disease, and obstructive sleep apnea, are also positively associated with LC [<xref rid="B35-idr-17-00056" ref-type="bibr">35</xref>,<xref rid="B39-idr-17-00056" ref-type="bibr">39</xref>,<xref rid="B40-idr-17-00056" ref-type="bibr">40</xref>]. Furthermore, pre-infection psychological distress significantly increases the risk of LC [<xref rid="B41-idr-17-00056" ref-type="bibr">41</xref>]. In a large prospective cohort study using data from Nurses&#x02019; Health Study (predominantly female cohorts), individuals experiencing two or more types of distress prior to infection had nearly a 50% higher risk of developing LC [<xref rid="B41-idr-17-00056" ref-type="bibr">41</xref>].</p></sec><sec id="sec4-idr-17-00056"><title>4. Materials and Methods</title><p>A systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [<xref rid="B42-idr-17-00056" ref-type="bibr">42</xref>] to evaluate prevention strategies for LC, including vaccines and antivirals. This study is registered on the International Platform of Registered Review and Meta-analysis Protocols (INPLASY) with the registration number INPLASY202530002. Two reviewers (SP and NN) independently assessed the quality and risk of bias of the studies, and any discrepancies were resolved through discussion.</p><p>LC was defined as persistent symptoms lasting three or more months and affecting one or more organ systems after SARS-CoV-2 infection, encompassing the definitions outlined by the WHO, NASEM, and CDC [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>]. We searched the PubMed/MEDLINE database for articles published between December 2019 and September 2024 using the following MeSH terms: &#x0201c;Post-Acute COVID-19 Syndrome (PACS)&#x0201d; AND &#x0201c;prevention and control&#x0201d;, &#x0201c;PACS&#x0201d; AND &#x0201c;Vaccines&#x0201d;, &#x0201c;PACS&#x0201d; AND &#x0201c;remdesivir (Gilead Sciences, Inc., Foster City, CA, USA)&#x0201d;, &#x0201c;PACS&#x0201d; AND &#x0201c;nirmatrelvir (Pfizer Inc., New York, NY, USA )&#x0201d;, and &#x0201c;PACS&#x0201d; AND &#x0201c;molnupiravir (Merck &#x00026; Co., Inc., Rahway, NJ, USA)&#x0201d;.</p><p>We included articles that met the following criteria: (1) study population consisting of adults aged 18 years or older, (2) LC being defined as described above, and (3) individuals who were categorized as vaccinated or treated received vaccines or treatment before the onset of LC. We excluded the following studies: (1) studies that either did not define LC or defined LC with symptoms lasting less than 3 months, (2) studies that did not clearly indicate the timeline of vaccinations or treatment, and (3) studies that did not report a statistical significance value. For the purpose of this review, we did not include case reports or series, review articles, and meta-analyses.</p><p>Based on the above criteria, we included 28 studies [<xref rid="B43-idr-17-00056" ref-type="bibr">43</xref>,<xref rid="B44-idr-17-00056" ref-type="bibr">44</xref>,<xref rid="B45-idr-17-00056" ref-type="bibr">45</xref>,<xref rid="B46-idr-17-00056" ref-type="bibr">46</xref>,<xref rid="B47-idr-17-00056" ref-type="bibr">47</xref>,<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>,<xref rid="B49-idr-17-00056" ref-type="bibr">49</xref>,<xref rid="B50-idr-17-00056" ref-type="bibr">50</xref>,<xref rid="B51-idr-17-00056" ref-type="bibr">51</xref>,<xref rid="B52-idr-17-00056" ref-type="bibr">52</xref>,<xref rid="B53-idr-17-00056" ref-type="bibr">53</xref>,<xref rid="B54-idr-17-00056" ref-type="bibr">54</xref>,<xref rid="B55-idr-17-00056" ref-type="bibr">55</xref>,<xref rid="B56-idr-17-00056" ref-type="bibr">56</xref>,<xref rid="B57-idr-17-00056" ref-type="bibr">57</xref>,<xref rid="B58-idr-17-00056" ref-type="bibr">58</xref>,<xref rid="B59-idr-17-00056" ref-type="bibr">59</xref>,<xref rid="B60-idr-17-00056" ref-type="bibr">60</xref>,<xref rid="B61-idr-17-00056" ref-type="bibr">61</xref>,<xref rid="B62-idr-17-00056" ref-type="bibr">62</xref>,<xref rid="B63-idr-17-00056" ref-type="bibr">63</xref>,<xref rid="B64-idr-17-00056" ref-type="bibr">64</xref>,<xref rid="B65-idr-17-00056" ref-type="bibr">65</xref>]. Of these, fifteen focused on the impact of COVID-19 vaccination on LC, seven studied the impact of antivirals on LC, and six investigated the impact of other treatments on the development of LC (<xref rid="idr-17-00056-f001" ref-type="fig">Figure 1</xref>).</p><p>Additionally, we compared the impact of COVID-19 vaccines and antivirals with those when LC was defined as persistent symptoms lasting 28 days or longer, as there are a significant number of studies with this definition.</p></sec><sec sec-type="results" id="sec5-idr-17-00056"><title>5. Results</title><p>Unless specified otherwise, the findings refer to LC being defined as persistent symptoms lasting 3 months or longer.</p><sec id="sec5dot1-idr-17-00056"><title>5.1. Impact of COVID-19 Vaccine on Prevention of Long COVID</title><p>We identified fifteen articles focused on the impact of COVID-19 vaccination on LC. Unless described by the authors, COVID-19 infection before January 2021 is categorized as wild type, infection between January 2021 and June 2021 as the Alpha variant, infection between July and December 2021 as the Delta variant, and infection from January 2022 onwards as the Omicron variant (<xref rid="idr-17-00056-t001" ref-type="table">Table 1</xref>). We specified vaccine types when the information was available (<xref rid="idr-17-00056-t001" ref-type="table">Table 1</xref>).</p><p>Of the fifteen articles, ten studies demonstrated a protective effect of vaccines against the development of LC (<xref rid="idr-17-00056-t001" ref-type="table">Table 1</xref>). Among five studies [<xref rid="B45-idr-17-00056" ref-type="bibr">45</xref>,<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>,<xref rid="B57-idr-17-00056" ref-type="bibr">57</xref>,<xref rid="B66-idr-17-00056" ref-type="bibr">66</xref>,<xref rid="B67-idr-17-00056" ref-type="bibr">67</xref>] that did not demonstrate a statistically significant protective effect on the development of LC, one study showed a trend towards protection [<xref rid="B67-idr-17-00056" ref-type="bibr">67</xref>], and two reported a reduction in a few LC symptoms due to vaccination [<xref rid="B45-idr-17-00056" ref-type="bibr">45</xref>,<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>]. In this section, we describe the identified prospective studies in detail and summarize identified retrospective and cross-sectional studies, focusing on the impact of vaccines on the development of LC. A summary of each selected study is described in <xref rid="idr-17-00056-t001" ref-type="table">Table 1</xref>.</p><p>Ayoubkhani et al. [<xref rid="B44-idr-17-00056" ref-type="bibr">44</xref>] conducted a prospective cohort study in the United Kingdom (UK) to determine the trajectory of LC in participants who were vaccinated after being diagnosed with COVID-19. The study included 28,356 participants who had at least one visit between February and September 2021 (Alpha and Delta variants), a test confirming COVID-19 diagnosis at least 12 weeks before the final visit, and had received a vaccine after the diagnosis of COVID-19 but before the above study period. The odds of developing LC decreased by 12.8% after the first vaccine dose (BNT162b2, mRNA-1273, or ChAdOx1) compared to unvaccinated individuals and then decreased by an additional 8.8% after the second vaccine dose.</p><p>Antonelli et al. [<xref rid="B66-idr-17-00056" ref-type="bibr">66</xref>] investigated the effect of a third dose of (booster) of a monovalent vaccine compared to a second dose during the Delta and Omicron eras, separately, through a prospective community-based case&#x02013;control study in the UK. The study included COVID-19 patients from June 2021 to April 2022, with 1910 patients in each group during the Delta period and 7894 in each group during the Omicron period. The booster vaccination did not reduce the risk of LC when it was defined as symptoms persisting for 12 weeks or longer despite a trend towards a protective effect. The booster vaccination reduced the risk of LC when LC was defined as symptoms persisting for 4 weeks or longer during the Delta period, but not during the Omicron period.</p><p>A prospective longitudinal cohort study was carried out by Richard et al. [<xref rid="B67-idr-17-00056" ref-type="bibr">67</xref>] in the USA using data from the Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study. The study population consisted of 1832 military personnel aged 18 to 44 years who tested positive for SARS-CoV-2 from February 2020 to December 2021 (wild type and Alpha and Delta variants). Fully vaccinated individuals (two doses of BNT162b2 or mRNA-1273 or one dose of Ad26.COV2.S) were 27% less likely to develop LC, though the difference was not statistically significant (<italic toggle="yes">p</italic> = 0.17). However, when LC was defined as symptoms persisting 4 weeks, the risk was reduced by 28% with statistical significance (<italic toggle="yes">p</italic> = 0.02).</p><p>Nehme et al. [<xref rid="B59-idr-17-00056" ref-type="bibr">59</xref>] compared the prevalence of LC symptoms between individuals infected with COVID-19 (Omicron variants BA.1 and BA.2) (total 1807) and uninfected individuals (total 882), as well as between fully vaccinated (at least two doses of mRNA-1273 or BNT162b2 before COVID-19) and unvaccinated individuals. This study included individuals who were diagnosed with Omicron infection between December 2021 and February 2022 at the Geneva University Hospitals outpatient testing center and were contacted 3 months from their test date. Overall, 11.7% of individuals infected with Omicron had LC symptoms compared to 10.4% of individuals who tested negative (<italic toggle="yes">p</italic> &#x0003c; 0.001). LC symptoms were less common in fully vaccinated individuals compared to unvaccinated individuals (adjusted prevalence of 9.7% vs. 18.1%; <italic toggle="yes">p</italic> &#x0003c; 0.001)</p><p>A prospective cohort study by Brunvoll et al. [<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>] included 1420 participants diagnosed with COVID-19 between November 2020 and October 2021 (wild type and Alpha and Delta variants) in Norway. The study found no differences in self-reported LC symptoms between fully vaccinated (at least two doses of mRNA) and unvaccinated individuals, except vaccinated individuals reported fewer memory problems. However, the study found no differences in Everyday Memory Questionnaire-13 (EMQ-13) scores between vaccinated and unvaccinated individuals.</p><p>Abu Hamdh et al. [<xref rid="B43-idr-17-00056" ref-type="bibr">43</xref>] carried out a prospective cohort study in Palestine, including 669 patients diagnosed with COVID-19 between September 2021 and January 2022 (Delta variant), of whom 6.7% required hospitalization. A total of 41% patients received at least one dose of vaccine (BNT162b2, Sputnik Light, mRNA-1273, Sputnik V, or ChAdOx1) before their COVID-19 diagnosis. Vaccinated patients with at least one dose had 85% lower odds of developing LC compared to unvaccinated patients.</p><p>Another prospective study in Pakistan, including a total of 481 hospitalized patients with COVID-19 between February and June 2021 (Alpha variant) [<xref rid="B54-idr-17-00056" ref-type="bibr">54</xref>], showed that fully or partially vaccinated patients were less likely to develop LC compared to unvaccinated patients, with adjusted odds ratios (aORs) of 0.38 (95% CI: 0.20&#x02013;0.70) and 0.44 (95% CI: 0.24&#x02013;0.80), respectively. Similarly, a prospective study conducted in Brazil involving 412 hospitalized patients diagnosed with COVID-19 between May 2021 and February 2022 (Alpha, Delta, and Omega variants) [<xref rid="B68-idr-17-00056" ref-type="bibr">68</xref>] demonstrated that being fully vaccinated (at least one dose of Janssen or two doses of other vaccines) reduced the odds of developing LC (aOR = 0.55, <italic toggle="yes">p</italic> = 0.007).</p><p>A staggered retrospective cohort at the population level was carried out by Catal&#x000e0; et al. [<xref rid="B49-idr-17-00056" ref-type="bibr">49</xref>] using primary care records from the United Kingdom (UK) (Clinical Practice Research Datalink [CPRD] GOLD and CPRD AURUM), Spain (the Information System for Research in Primary care [SIDIAP]), and Estonia (CORIVA database), which included over 10 million vaccinated and over 10 million unvaccinated people. Analyses included both patients infected with COVID-19 and uninfected patients to assess vaccines&#x02019; effect in preventing COVID-19 and subsequent LC. Individuals were registered by January or February 2021 and followed up through December 2022 (Alpha, Delta, Omicron variants), and vaccination status was staggered based on the vaccine rollout period. COVID-19 vaccination (at least one dose of BNT162b2, ChAdOx1, mRNA-1273, or Ad26.COV2.S) showed a significant protective effect against developing LC, with overall vaccine effectiveness ranging from 29% to 52%. Trinh et al. [<xref rid="B61-idr-17-00056" ref-type="bibr">61</xref>] conducted the same analyses as Catal&#x000e0; et al. [<xref rid="B49-idr-17-00056" ref-type="bibr">49</xref>] using the Norwegian Linked Health Registries at University of Oslo, which covers the entire Norwegian population of approximately 5.4 million, and demonstrated a reproducible and significant protective effect of vaccines against developing LC with 36% effectiveness.</p><p>Luo et al. [<xref rid="B57-idr-17-00056" ref-type="bibr">57</xref>] performed a retrospective cohort in Hong Kong using electronic and telephone follow-up records for COVID-19 patients diagnosed between December 2021 and May 2022 (predominantly Omicron variant), with a follow-up of 6 to 12 months. They found that receiving a booster vaccine (three or more doses of BNT162b2 or CoronaVac) did not reduce the risk of LC compared to fewer doses before COVID-19. However, vaccination after infection increased the risk of reporting LC symptoms, which may be due to side effects from vaccination. MacCallum-Bridges et al. [<xref rid="B58-idr-17-00056" ref-type="bibr">58</xref>] conducted a population-based retrospective cohort study, using data from the Michigan COVID-19 Recovery Surveillance Study for participants diagnosed with COVID-19 between March 2020 and May 2022 (wild type and Alpha, Delta, and Omicron variants), which found a 58% lower adjusted prevalence of 90-day LC in the fully vaccinated group (two doses of BNT162b2, mRNA-1273, ChAdOx1, or Sinovac or one dose of Ad26.COV2.S) compared to the unvaccinated group. Babicki et al. [<xref rid="B45-idr-17-00056" ref-type="bibr">45</xref>] conducted a retrospective study in Poland using data from the STOP-COVID registry (unknown study period), with 9.4% individuals being vaccinated before COVID-19 and 73.6% after. Full vaccination (two doses of BNT162b2, mRNA-1273 or ChAdOx1 or one dose of Ad26.COV2.S) had no impact on the development of LC, although headache, arthralgia, and a new diagnosis of hypertension were less common in vaccinated individuals regardless of the timeline of vaccination.</p><p>Woldeglorgis et al. [<xref rid="B63-idr-17-00056" ref-type="bibr">63</xref>] assessed LC prevalence 90 days post COVID-19 in highly vaccinated Western Australian adults between July and August 2022 (Omicron variant). Those with 0&#x02013;2 vaccine doses had a 1.4-fold higher risk, and those with 3 doses had a 1.3-fold higher risk of developing LC compared to individuals with 4 or more doses. Xie et al. [<xref rid="B64-idr-17-00056" ref-type="bibr">64</xref>], using data from the 2022 National Health Interview Survey of the United States adults (Omicron variant), showed that individuals who received a booster dose had 25% lower odds of developing LC compared to unvaccinated individuals.</p><p>Among eleven studies [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>,<xref rid="B44-idr-17-00056" ref-type="bibr">44</xref>,<xref rid="B69-idr-17-00056" ref-type="bibr">69</xref>,<xref rid="B70-idr-17-00056" ref-type="bibr">70</xref>,<xref rid="B71-idr-17-00056" ref-type="bibr">71</xref>,<xref rid="B72-idr-17-00056" ref-type="bibr">72</xref>,<xref rid="B73-idr-17-00056" ref-type="bibr">73</xref>,<xref rid="B74-idr-17-00056" ref-type="bibr">74</xref>,<xref rid="B75-idr-17-00056" ref-type="bibr">75</xref>,<xref rid="B76-idr-17-00056" ref-type="bibr">76</xref>,<xref rid="B77-idr-17-00056" ref-type="bibr">77</xref>] that defined LC as persistent symptoms lasting 28 days or longer, ten studies, including two prospective studies [<xref rid="B70-idr-17-00056" ref-type="bibr">70</xref>,<xref rid="B72-idr-17-00056" ref-type="bibr">72</xref>] and eight retrospective studies [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>,<xref rid="B44-idr-17-00056" ref-type="bibr">44</xref>,<xref rid="B69-idr-17-00056" ref-type="bibr">69</xref>,<xref rid="B71-idr-17-00056" ref-type="bibr">71</xref>,<xref rid="B73-idr-17-00056" ref-type="bibr">73</xref>,<xref rid="B74-idr-17-00056" ref-type="bibr">74</xref>,<xref rid="B75-idr-17-00056" ref-type="bibr">75</xref>,<xref rid="B76-idr-17-00056" ref-type="bibr">76</xref>], showed a protective effect of COVID-19 vaccines (<xref rid="app1-idr-17-00056" ref-type="app">Table S1</xref>).</p></sec><sec id="sec5dot2-idr-17-00056"><title>5.2. The Impact of Antivirals on the Prevention of Long COVID</title><p>A total of seven studies met our inclusion criteria under this section. We identified one randomized trial, three prospective studies, and three retrospective studies. A summary of each study is described in <xref rid="idr-17-00056-t002" ref-type="table">Table 2</xref>.</p><p>Among the three studies that evaluated the impact of remdesivir on the prevention of LC in hospitalized patients, a randomized trial [<xref rid="B60-idr-17-00056" ref-type="bibr">60</xref>] found no differences between remdesivir-treated and untreated groups, while a prospective study [<xref rid="B78-idr-17-00056" ref-type="bibr">78</xref>] and a retrospective case&#x02013;control study [<xref rid="B55-idr-17-00056" ref-type="bibr">55</xref>] demonstrated that remdesivir had a protective effect, as described below.</p><p>Nevalainen et al. [<xref rid="B60-idr-17-00056" ref-type="bibr">60</xref>] reported a one-year follow-up of the randomized SOLIDARITY Finland trial on the effects of remdesivir on recovery and LC symptoms. Among 181 patients recruited from 11 Finnish hospitals between July 2020 and January 2021 (wild type) who completed the 1-year survey, no significant differences were found in self-reported recovery or LC symptoms between remdesivir-treated and untreated groups. A prospective study conducted by Boglione et al. [<xref rid="B78-idr-17-00056" ref-type="bibr">78</xref>] included 163 remdesivir-treated and 165 untreated patients who were hospitalized for COVID-19 during the March 2020-January 2021 period (wild type and the Alpha variant) at Saint Andrea hospital in Vercelli, Italy. The study showed a 36% reduction in the odds of developing LC in the remdesivir-treated group. A case&#x02013;control study by Fern&#x000e1;ndez-de-las-Pe&#x000f1;as et al. [<xref rid="B55-idr-17-00056" ref-type="bibr">55</xref>] included hospitalized COVID-19 patients from urban hospitals in Madrid, Spain, between September 2020 and March 2021 (wild type and the Alpha variant). The odds of developing LC symptoms following acute COVID-19 infection was 60% lower in patients treated with remdesivir during their acute infection compared to the patients who were not treated with remdesivir.</p><p>Among the three studies that evaluated the impact of nirmatrelvir/ritonavir on the prevention of LC, a prospective study [<xref rid="B62-idr-17-00056" ref-type="bibr">62</xref>] demonstrated a protective effect, while the other prospective cohort [<xref rid="B53-idr-17-00056" ref-type="bibr">53</xref>] and a retrospective cohort [<xref rid="B51-idr-17-00056" ref-type="bibr">51</xref>] did not.</p><p>A prospective cohort study conducted by Durstenfeld et al. in the United States (US) [<xref rid="B53-idr-17-00056" ref-type="bibr">53</xref>] involved patients diagnosed with COVID-19 between March and August 2022 (Omicron variant), utilizing data from the COVID Citizen Science (CCS) study. This study, which included 353 patients treated with nirmatrelvir/ritonavir and 1258 untreated patients, demonstrated that nirmatrelvir/ritonavir did not reduce the risk of LC at 3 months or later post COVID-19 infection based on a propensity-adjusted model. Unlike the above study, Wang et al. [<xref rid="B62-idr-17-00056" ref-type="bibr">62</xref>] demonstrated a protective effect of nirmatrelvir/ritonavir in the development of LC in their prospective cohort study in China, which involved COVID-19 patients discharged between April and June 2022 (Omicron variant); nirmatrelvir/ritonavir treatment during hospitalization (178 out of 634 patients received nirmatrelvir/ritonavir) reduced the odds of developing LC by 65% 6 months after hospital discharge. In a retrospective cohort study by Congdon et al. including 500 COVID-19 patients in New York, USA, from May to November 2022 (Omicron variant) [<xref rid="B51-idr-17-00056" ref-type="bibr">51</xref>], nirmatrelvir/ritonavir was not associated with a significant reduction in the overall risk of developing LC.</p><p>Lastly, a retrospective study by Bertuccio et al. [<xref rid="B46-idr-17-00056" ref-type="bibr">46</xref>] showed a protective effect of antivirals, such as remdesivir, molnupiravir, or nirmatrelvir/ritonavir. Bertuccio et al. [<xref rid="B46-idr-17-00056" ref-type="bibr">46</xref>] included 649 outpatients with mild to moderate COVID-19 in Lombardy, Northern Italy, and had at least one risk factor for disease progression between April 2021 and March 2022 (Alpha, Delta, and Omicron variants). Patients treated with antivirals, including remdesivir, molnupiravir, and nirmatrelvir/ritonavir, had a 57% reduction in the odds of developing any symptoms compared to those not treated with antivirals. Additionally, patients treated with monoclonal antibodies (mAbs) had a 52% reduction in the odds of developing neuro-behavioral symptoms compared to those not treated with mAbs.</p><p>Among four retrospective studies [<xref rid="B79-idr-17-00056" ref-type="bibr">79</xref>,<xref rid="B80-idr-17-00056" ref-type="bibr">80</xref>,<xref rid="B81-idr-17-00056" ref-type="bibr">81</xref>,<xref rid="B82-idr-17-00056" ref-type="bibr">82</xref>] that defined LC as persistent symptoms lasting 28 days or longer, three studies [<xref rid="B79-idr-17-00056" ref-type="bibr">79</xref>,<xref rid="B81-idr-17-00056" ref-type="bibr">81</xref>,<xref rid="B82-idr-17-00056" ref-type="bibr">82</xref>] showed that nirmatrelvir or molnupiravir had a protective effect (<xref rid="app1-idr-17-00056" ref-type="app">Table S2</xref>).</p></sec><sec id="sec5dot3-idr-17-00056"><title>5.3. The Impact of Other Treatments on the Prevention of Long COVID</title><p>Six studies met the inclusion criteria under this section, including three randomized trials, one secondary analysis of a randomized clinical trial, and two retrospective cohorts. A randomized clinical trial in outpatients [<xref rid="B56-idr-17-00056" ref-type="bibr">56</xref>] and a secondary analysis of a randomized clinical trial in hospitalized patients [<xref rid="B65-idr-17-00056" ref-type="bibr">65</xref>] found no protective effect of COVID-19 convalescent plasma (CCP) on the development of LC. In contrast, a randomized trial by Bramante et al. [<xref rid="B47-idr-17-00056" ref-type="bibr">47</xref>] demonstrated that metformin reduced LC risk in outpatients, and two retrospective cohort studies [<xref rid="B50-idr-17-00056" ref-type="bibr">50</xref>,<xref rid="B52-idr-17-00056" ref-type="bibr">52</xref>] demonstrated a protective effect of corticosteroids in hospitalized patients. Lastly, multiple micronutrient supplements did not demonstrate a protective effect in a randomized trial [<xref rid="B83-idr-17-00056" ref-type="bibr">83</xref>]. A summary of each study is presented in <xref rid="idr-17-00056-t003" ref-type="table">Table 3</xref>.</p><p>Gebo et al. [<xref rid="B56-idr-17-00056" ref-type="bibr">56</xref>] conducted a double-blind multicenter randomized controlled trial involving 1225 symptomatic COVID-19 outpatients from June 2020 to October 2021 (wild type and Alpha and Delta variants) across 23 sites in the USA, with a 90-day follow-up after CCP transfusion. While there was no statistically significant reduction in the odds of self-reported LC symptoms at 90 days for those who received CCP within 5 days of illness compared to the control group, a trend towards lower odds of LC was observed. Yoon et al. [<xref rid="B65-idr-17-00056" ref-type="bibr">65</xref>] conducted a secondary analysis of a blinded, multicenter randomized controlled trial involving 281 hospitalized COVID-19 patients from April 2020 to March 2021 (wild type and Alpha variant), with an 18-month follow-up. The study found no significant differences in the odds of developing LC between the CCP and placebo groups.</p><p>Bramante et al. [<xref rid="B47-idr-17-00056" ref-type="bibr">47</xref>] carried out a multi-site, phase 3, randomized quadruple-blinded placebo-controlled trial to assess whether early treatment with metformin, ivermectin, or fluvoxamine could prevent LC in COVID-19 outpatients with overweight or obesity. Patients were enrolled within 3 days of COVID-19 diagnosis and within 7 days of symptom onset between December 2020 and January 2022 (wild type and Alpha, Delta, and Omicron variants). The metformin group showed a 42% reduction in LC incidence compared to the control, while ivermectin or fluvoxamine showed no effect.</p><p>Two retrospective cohort studies demonstrated that corticosteroid treatment lowered the risk of developing LC&#x02014;one was conducted in the Netherlands and involved hospitalized COVID-19 patients between March 2020 and September 2021 (wild type and Alpha and Delta variants) with the criteria for corticosteroid use being a respiratory rate of &#x0003e;25 breaths per minute, an oxygen requirement of &#x0003e;5 L, or a rapidly increasing oxygen requirement [<xref rid="B52-idr-17-00056" ref-type="bibr">52</xref>], and another was conducted in Spain in hospitalized COVID-19 patients between March and May 2020 (wild type) [<xref rid="B50-idr-17-00056" ref-type="bibr">50</xref>]. The criteria for corticosteroid use were not mentioned in the study performed in Spain [<xref rid="B50-idr-17-00056" ref-type="bibr">50</xref>].</p><p>Two centers in Catalonia, Spain, investigated the effect of a multiple micronutrient supplement (MMS), comprising Vitamins A, B6, B12, C, D3, E, copper, folic acid, iron, selenium, and zinc, on LC incidence in a double-blind, placebo-controlled, randomized clinical trial. The study included 246 patients with mild COVID-19 (not requiring hospital admission) between September 2021 and February 2023 (Delta and Omicron variants). The trial found no differences in LC incidence between the intervention group (MMS for 2 weeks starting on day 1 of inclusion) and the placebo groups [<xref rid="B83-idr-17-00056" ref-type="bibr">83</xref>].</p></sec></sec><sec sec-type="discussion" id="sec6-idr-17-00056"><title>6. Discussion</title><p>Long COVID (LC) poses significant medical, social, and economic impacts worldwide [<xref rid="B3-idr-17-00056" ref-type="bibr">3</xref>]. The underlying mechanisms of LC remain elusive. The proposed mechanisms are not mutually exclusive and may interact with each other, leading to a complex and varied clinical presentation seen in patients with LC. The risk factors are not easily modifiable. Based on that, our systematic review focused on modifiable preventive strategies for LC.</p><p>Despite the numerous studies on LC, research on its prevention remains challenging due to the evolving nature of the virus, the lack of unique biomarkers for diagnosing LC, and variations in LC&#x02019;s definition [<xref rid="B2-idr-17-00056" ref-type="bibr">2</xref>]. Additionally, different types of SARS-CoV-2 variants and existing immunity against COVID-19 can influence LC&#x02019;s incidence or prevalence [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>]. The definitions of LC used in studies, along with inclusion or exclusion criteria, study design and methods, and study setting (e.g., inpatient-based or outpatient-based), can significantly affect the effect size and outcomes of interventions as well [<xref rid="B84-idr-17-00056" ref-type="bibr">84</xref>]. Furthermore, LC symptoms appear to evolve over time; therefore, study outcomes may vary depending on the timing of the LC assessment after a COVID-19 diagnosis [<xref rid="B84-idr-17-00056" ref-type="bibr">84</xref>].</p><sec id="sec6dot1-idr-17-00056"><title>6.1. COVID-19 Vaccines Reduce the Risk of Long COVID</title><p>Except for two large staggered retrospective cohorts [<xref rid="B49-idr-17-00056" ref-type="bibr">49</xref>,<xref rid="B61-idr-17-00056" ref-type="bibr">61</xref>], most studies only included patients diagnosed with COVID-19 to assess the effect of vaccines&#x02014;likely underestimating the true impact of vaccines as COVID-19 vaccines reduce the risk of infection and the severity of illness [<xref rid="B85-idr-17-00056" ref-type="bibr">85</xref>] and, consequently, LC. Nevertheless, most of these studies (ten out of fifteen) demonstrated that COVID-19 vaccines have a significant overall protective effect against developing LC.</p><p>There are several plausible reasons why some vaccine-related studies failed to show a protective effect. A booster compared to the primary series did not show a statistically significant protective effect in two included studies conducted during the Delta/Omicron and Omicron periods, respectively [<xref rid="B57-idr-17-00056" ref-type="bibr">57</xref>,<xref rid="B66-idr-17-00056" ref-type="bibr">66</xref>]. This finding is consistent with a recent meta-analysis [<xref rid="B8-idr-17-00056" ref-type="bibr">8</xref>]. In contrast, a cross-sectional study included in our review, conducted in Australia [<xref rid="B63-idr-17-00056" ref-type="bibr">63</xref>], found a dose&#x02013;response benefit of vaccination against LC during the Omicron period. While further studies are needed to elucidate this, it is possible that booster vaccination may not provide substantial additional protection against LC beyond that provided by the primary vaccine series.</p><p>The unique study population and/or low vaccination rates due to vaccine unavailability during the early pandemic period may have reduced the statistical power of the following two included studies to detect a protective effect. Richard et al. [<xref rid="B67-idr-17-00056" ref-type="bibr">67</xref>] recruited young military personnel, only 22.9% of whom were fully vaccinated&#x02014;partly due to the inclusion of individuals from the wild-type era and the younger age of the cohort. Of the participants in the study by Brunvoll et al. [<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>], which also included individuals from the wild type era, only 25% were vaccinated, likely because a significant portion of the participants were infected before vaccines became widely available.</p><p>Vaccination after COVID-19 infection is likely less protective against LC compared to vaccination before infection [<xref rid="B8-idr-17-00056" ref-type="bibr">8</xref>]. Most participants (73.6%) in the study by Babicki et al. [<xref rid="B45-idr-17-00056" ref-type="bibr">45</xref>] were vaccinated after COVID-19 infection, which may explain the lack of a protective effect.</p><p>Over time, LC rates have declined, associated with viral variants and vaccination, with the highest rate observed in the pre-Delta era, followed by the Delta era and the Omicron era [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>]. Additionally, there are significant differences in LC rates and vaccine dose requirements for protection depending on the COVID-19 era [<xref rid="B13-idr-17-00056" ref-type="bibr">13</xref>]. Therefore, comparisons from different COVID-19 eras can introduce a selection bias and lead to erroneous results. For example, staggered cohorts [<xref rid="B49-idr-17-00056" ref-type="bibr">49</xref>,<xref rid="B61-idr-17-00056" ref-type="bibr">61</xref>] selected equivalent numbers of vaccinated and unvaccinated individuals from each era to avoid selection bias. However, studies [<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>,<xref rid="B58-idr-17-00056" ref-type="bibr">58</xref>,<xref rid="B67-idr-17-00056" ref-type="bibr">67</xref>] which included patients across different COVID-19 eras, including the wild-type era, may have disproportionately selected patients from the early COVID-19 eras, when vaccines were unavailable or vaccination rates were low, and LC rates were likely high. This selection method could have introduced a bias in the estimates.</p><p>Despite differences in patient populations, designs, methods, and the type of SARS-CoV-2 variant, COVID-19 vaccines are generally protective against LC. We found a stronger effect of vaccines when LC was defined as symptoms lasting 28 days or longer (<xref rid="app1-idr-17-00056" ref-type="app">Table S1</xref>), which implies that COVID-19 vaccines reduce both acute COVID-19 illness and LC symptoms.</p></sec><sec id="sec6dot2-idr-17-00056"><title>6.2. Equivocal Evidence for Protective Effect of Antivirals and Other Drugs</title><p>Studies have yielded mixed results, potentially due to differences in study design, patient population, study setting, the timing of antivirals, and possible measurement biases. Three studies (wild type and Alpha variant) on remdesivir demonstrated conflicting results; a randomized study demonstrated no effect [<xref rid="B60-idr-17-00056" ref-type="bibr">60</xref>], but a prospective study [<xref rid="B78-idr-17-00056" ref-type="bibr">78</xref>] and a retrospective case&#x02013;control study demonstrated a protective effect on the development of LC [<xref rid="B55-idr-17-00056" ref-type="bibr">55</xref>]. The randomized study assessed LC symptoms 1 year after COVID-19, whereas the other two studies assessed them 12 weeks after COVID-19 or later. In addition to differences in the study design and patient population, the timing of symptom assessment may have contributed to different results.</p><p>Similarly, the results for nirmatrelvir/ritonavir also varied by study design, setting, and patient population. A prospective study of hospitalized patients in China [<xref rid="B62-idr-17-00056" ref-type="bibr">62</xref>] and a retrospective study of outpatients in Italy [<xref rid="B46-idr-17-00056" ref-type="bibr">46</xref>] demonstrated a protective effect of nirmatrelvir/ritonavir, whereas a prospective cohort study and a retrospective study in the US involving outpatients did not demonstrate a protective effect [<xref rid="B51-idr-17-00056" ref-type="bibr">51</xref>,<xref rid="B53-idr-17-00056" ref-type="bibr">53</xref>]. In the US, the Food and Drug Administration (FDA) approved the use of nirmatrelvir/ritonavir to treat mild to moderate COVID-19 to prevent severe infection [<xref rid="B86-idr-17-00056" ref-type="bibr">86</xref>], so nirmatrelvir/ritonavir has hardly been used in inpatient settings. While further studies on this topic are necessary to reach a more definite conclusion, inconsistent results indicate the uncertain effect of antivirals in preventing LC. It is possible that immune activation triggered by COVID-19, which contributes to the development of LC, may not be easily mitigated by antivirals.</p><p>A protective effect of antivirals against LC was more notable when LC was defined as symptoms lasting 28 days or longer, which indicates that antivirals may help reduce the symptoms of acute COVID-19 illness as symptoms of acute COVID-19 can last longer than 28 days.</p><p>A randomized study and a secondary analysis of a randomized study [<xref rid="B56-idr-17-00056" ref-type="bibr">56</xref>,<xref rid="B65-idr-17-00056" ref-type="bibr">65</xref>] did not demonstrate a protective effect of COVID-19 convalescent plasma transfusion on the development of LC in outpatient and hospitalized settings. However, a randomized study demonstrated a protective effect of metformin use in COVID-19 outpatients with overweight or obesity [<xref rid="B47-idr-17-00056" ref-type="bibr">47</xref>]. In addition, two retrospective studies demonstrated a protective effect of corticosteroid use in hospitalized COVID-19 patients on the development of LC [<xref rid="B50-idr-17-00056" ref-type="bibr">50</xref>,<xref rid="B52-idr-17-00056" ref-type="bibr">52</xref>]. Further studies would be valuable in understanding the underlying mechanisms and impact of these drugs on LC.</p></sec><sec id="sec6dot3-idr-17-00056"><title>6.3. Effect of Nutrients and Lifestyle Factors on Long COVID</title><p>Besides vaccines, antivirals, and the above medications, other factors such as nutrients and lifestyle factors may play an important role in the development of LC. While a randomized study did not demonstrate a protective effect of multiple micronutrient supplements (MMSs) on LC incidence [<xref rid="B83-idr-17-00056" ref-type="bibr">83</xref>], it is possible that a longer duration of MMS use could yield different results. A prospective UK cohort study examining the association between modifiable lifestyle factors prior to COVID-19 and LC (with LC defined as symptoms lasting 30 days or longer) demonstrated that the risk of LC was reduced with a favorable lifestyle compared to an unfavorable lifestyle [<xref rid="B87-idr-17-00056" ref-type="bibr">87</xref>]. Additional studies on modifiable lifestyle factors to prevent LC are also warranted, especially since lifestyle modification can be potentially achievable at a low cost and with minimal adverse effects.</p></sec><sec id="sec6dot4-idr-17-00056"><title>6.4. Limitations</title><p>Our study has several limitations. We might have missed some studies due to our inclusion criteria, although our review was comprehensive, extending to vaccine- and antiviral-related studies that defined LC as symptoms lasting 28 days or longer. There are no randomized trials to assess the impact of vaccines on the development of LC, although the majority of the studies demonstrate that vaccines have a robust protective effect. There is a limited number of studies for antivirals and other treatments; therefore, drawing a conclusion requires caution. The included studies assessed LC at different time points to determine the impact of vaccines, antivirals, or other treatments, which could have influenced the study outcomes. Due to heterogeneity in study designs and methods, statistical outcomes could not be uniformly reported.</p></sec></sec><sec sec-type="conclusions" id="sec7-idr-17-00056"><title>7. Conclusions</title><p>Long COVID is a serious global burden that has impacted millions of individuals worldwide [<xref rid="B2-idr-17-00056" ref-type="bibr">2</xref>]. To the best of our knowledge, our study is the first systematic review addressing various preventive strategies for LC, particularly using the LC consensus definition.</p><p>Based on the data available at this time, COVID-19 vaccines likely reduce the risk of developing LC; however, evidence for antivirals and other drugs in preventing LC is still in its infancy. Future randomized, multicenter studies would offer valuable insights to (1) strengthen the evidence on the protection provided by COVID-19 vaccines against LC; (2) understand the impact of booster vaccines, antivirals, and other drugs on LC; and (3) understand the role of lifestyles in developing LC.</p><p>A lack of biomarkers that can assist in predicting or diagnosing LC hinders us from effectively preventing LC. Studies aiming to identify biomarkers that can predict the development of LC or diagnose LC are crucial to reduce the burden of LC. As our understanding of the pathophysiology of LC matures, our diagnostic, therapeutic, and preventive options will evolve, which will eventually reduce the morbidity associated with LC.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-idr-17-00056"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/idr17030056/s1">https://www.mdpi.com/article/10.3390/idr17030056/s1</uri>, Table S1: Impact of COVID-19 vaccination on prevention of long COVID: studies that defined long COVID as symptoms lasting more than 28 days; Table S2: Impact of antivirals on prevention of long COVID: studies that defined long COVID as symptoms lasting more than 28 days.</p><supplementary-material id="idr-17-00056-s001" position="float" content-type="local-data"><media xlink:href="idr-17-00056-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.O.P. and N.N.; methodology, S.O.P. and N.N.; formal analysis, S.O.P. and N.N.; writing-original draft preparation, S.O.P.; writing-review and editing, S.O.P. and N.N.; supervision, N.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-idr-17-00056"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention</collab>
</person-group><article-title>COVID-19 Timeline</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/museum/timeline/covid19.html" ext-link-type="uri">https://www.cdc.gov/museum/timeline/covid19.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-07">(accessed on 7 December 2024)</date-in-citation></element-citation></ref><ref id="B2-idr-17-00056"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ely</surname><given-names>E.W.</given-names></name>
<name><surname>Brown</surname><given-names>L.M.</given-names></name>
<name><surname>Fineberg</surname><given-names>H.V.</given-names></name>
<collab>National Academies of Sciences Engineering</collab>
<collab>Medicine Committee on Examining the Working Definition for Long Covid</collab>
</person-group><article-title>Long Covid Defined</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>391</volume><fpage>1746</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1056/NEJMsb2408466</pub-id><pub-id pub-id-type="pmid">39083764</pub-id>
</element-citation></ref><ref id="B3-idr-17-00056"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Committee on Examining the Working Definition for Long COVID (Washington District of Columbia)</collab>
</person-group><source>A Long Covid Definition: A Chronic, Systemic Disease State with Profound Consequences</source><publisher-name>National Academies Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B4-idr-17-00056"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Post COVID-19 Condition (Long COVID)</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition" ext-link-type="uri">https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-07">(accessed on 7 December 2024)</date-in-citation></element-citation></ref><ref id="B5-idr-17-00056"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Global Burden of Disease Long COVID Collaborators</collab>
<name><surname>Wulf Hanson</surname><given-names>S.</given-names></name>
<name><surname>Abbafati</surname><given-names>C.</given-names></name>
<name><surname>Aerts</surname><given-names>J.G.</given-names></name>
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
<name><surname>Ashbaugh</surname><given-names>C.</given-names></name>
<name><surname>Ballouz</surname><given-names>T.</given-names></name>
<name><surname>Blyuss.</surname><given-names>O.</given-names></name>
<name><surname>Bobkova</surname><given-names>P.</given-names></name>
<name><surname>Bonsel</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Estimated Global Proportions of Individuals with Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>1604</fpage><lpage>1615</lpage><pub-id pub-id-type="pmid">36215063</pub-id>
</element-citation></ref><ref id="B6-idr-17-00056"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carlile</surname><given-names>O.</given-names></name>
<name><surname>Briggs</surname><given-names>A.</given-names></name>
<name><surname>Henderson</surname><given-names>A.D.</given-names></name>
<name><surname>Butler-Cole</surname><given-names>B.F.C.</given-names></name>
<name><surname>Tazare</surname><given-names>J.</given-names></name>
<name><surname>Tomlinson</surname><given-names>L.A.</given-names></name>
<name><surname>Marks</surname><given-names>M.</given-names></name>
<name><surname>Jit</surname><given-names>M.</given-names></name>
<name><surname>Lin</surname><given-names>L.Y.</given-names></name>
<name><surname>Bates</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Impact of long COVID on health-related quality-of-life: An OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)</article-title><source>Lancet Reg. Health Eur.</source><year>2024</year><volume>40</volume><fpage>100908</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2024.100908</pub-id><pub-id pub-id-type="pmid">38689605</pub-id>
</element-citation></ref><ref id="B7-idr-17-00056"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>G.</given-names></name>
<name><surname>Lin</surname><given-names>K.</given-names></name>
<name><surname>Ai</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: A systematic review and meta-analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2024</year><volume>30</volume><fpage>1505</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2024.07.006</pub-id><pub-id pub-id-type="pmid">39002665</pub-id>
</element-citation></ref><ref id="B8-idr-17-00056"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chow</surname><given-names>N.K.N.</given-names></name>
<name><surname>Tsang</surname><given-names>C.Y.W.</given-names></name>
<name><surname>Chan</surname><given-names>Y.H.</given-names></name>
<name><surname>Telaga</surname><given-names>S.A.</given-names></name>
<name><surname>Ng</surname><given-names>L.Y.A.</given-names></name>
<name><surname>Chung</surname><given-names>C.M.</given-names></name>
<name><surname>Yip</surname><given-names>Y.M.</given-names></name>
<name><surname>Cheung</surname><given-names>P.P.</given-names></name>
</person-group><article-title>The effect of pre-COVID and post-COVID vaccination on long COVID: A systematic review and meta-analysis</article-title><source>J. Infect.</source><year>2024</year><volume>89</volume><fpage>106358</fpage><pub-id pub-id-type="doi">10.1016/j.jinf.2024.106358</pub-id><pub-id pub-id-type="pmid">39580033</pub-id>
</element-citation></ref><ref id="B9-idr-17-00056"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>H.E.</given-names></name>
<name><surname>McCorkell</surname><given-names>L.</given-names></name>
<name><surname>Vogel</surname><given-names>J.M.</given-names></name>
<name><surname>Topol</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Long COVID: Major findings, mechanisms and recommendations</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmid">36639608</pub-id>
</element-citation></ref><ref id="B10-idr-17-00056"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Liang</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><article-title>The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>416</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01640-z</pub-id><pub-id pub-id-type="pmid">37907497</pub-id>
</element-citation></ref><ref id="B11-idr-17-00056"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proal</surname><given-names>A.D.</given-names></name>
<name><surname>VanElzakker</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Long COVID or Post-Acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>698169</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.698169</pub-id><pub-id pub-id-type="pmid">34248921</pub-id>
</element-citation></ref><ref id="B12-idr-17-00056"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Komaroff</surname><given-names>A.L.</given-names></name>
<name><surname>Lipkin</surname><given-names>W.I.</given-names></name>
</person-group><article-title>ME/CFS and Long COVID share similar symptoms and biological abnormalities: Road map to the literature</article-title><source>Front. Med.</source><year>2023</year><volume>10</volume><elocation-id>1187163</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1187163</pub-id></element-citation></ref><ref id="B13-idr-17-00056"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Choi</surname><given-names>T.</given-names></name>
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
</person-group><article-title>Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>391</volume><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2403211</pub-id><pub-id pub-id-type="pmid">39018527</pub-id>
</element-citation></ref><ref id="B14-idr-17-00056"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proal</surname><given-names>A.D.</given-names></name>
<name><surname>VanElzakker</surname><given-names>M.B.</given-names></name>
<name><surname>Aleman</surname><given-names>S.</given-names></name>
<name><surname>Bach</surname><given-names>K.</given-names></name>
<name><surname>Boribong</surname><given-names>B.P.</given-names></name>
<name><surname>Buggert</surname><given-names>M.</given-names></name>
<name><surname>Cherry</surname><given-names>S.</given-names></name>
<name><surname>Chertow</surname><given-names>D.S.</given-names></name>
<name><surname>Davies</surname><given-names>H.E.</given-names></name>
<name><surname>Dupont</surname><given-names>C.L.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)</article-title><source>Nat. Immunol.</source><year>2023</year><volume>24</volume><fpage>1616</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01601-2</pub-id><pub-id pub-id-type="pmid">37667052</pub-id>
</element-citation></ref><ref id="B15-idr-17-00056"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stein</surname><given-names>S.R.</given-names></name>
<name><surname>Ramelli</surname><given-names>S.C.</given-names></name>
<name><surname>Grazioli</surname><given-names>A.</given-names></name>
<name><surname>Chung</surname><given-names>J.Y.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Yinda</surname><given-names>C.K.</given-names></name>
<name><surname>Winkler</surname><given-names>C.W.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Dickey</surname><given-names>J.M.</given-names></name>
<name><surname>Ylaya</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 infection and persistence in the human body and brain at autopsy</article-title><source>Nature</source><year>2022</year><volume>612</volume><fpage>758</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05542-y</pub-id><pub-id pub-id-type="pmid">36517603</pub-id>
</element-citation></ref><ref id="B16-idr-17-00056"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swank</surname><given-names>Z.</given-names></name>
<name><surname>Senussi</surname><given-names>Y.</given-names></name>
<name><surname>Manickas-Hill</surname><given-names>Z.</given-names></name>
<name><surname>Yu</surname><given-names>X.G.</given-names></name>
<name><surname>Li</surname><given-names>J.Z.</given-names></name>
<name><surname>Alter</surname><given-names>G.</given-names></name>
<name><surname>Walt</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated with Post-Acute Coronavirus Disease 2019 Sequelae</article-title><source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source><year>2023</year><volume>76</volume><fpage>e487</fpage><lpage>e490</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac722</pub-id></element-citation></ref><ref id="B17-idr-17-00056"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glynne</surname><given-names>P.</given-names></name>
<name><surname>Tahmasebi</surname><given-names>N.</given-names></name>
<name><surname>Gant</surname><given-names>V.</given-names></name>
<name><surname>Gupta</surname><given-names>R.</given-names></name>
</person-group><article-title>Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines</article-title><source>J. Investig. Med.</source><year>2022</year><volume>70</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1136/jim-2021-002051</pub-id></element-citation></ref><ref id="B18-idr-17-00056"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klein</surname><given-names>J.</given-names></name>
<name><surname>Wood</surname><given-names>J.</given-names></name>
<name><surname>Jaycox</surname><given-names>J.R.</given-names></name>
<name><surname>Dhodapkar</surname><given-names>R.M.</given-names></name>
<name><surname>Lu</surname><given-names>P.</given-names></name>
<name><surname>Gehlhausen</surname><given-names>J.R.</given-names></name>
<name><surname>Tabachnikova</surname><given-names>A.</given-names></name>
<name><surname>Greene</surname><given-names>K.</given-names></name>
<name><surname>Tabacof</surname><given-names>L.</given-names></name>
<name><surname>Malik</surname><given-names>A.A.</given-names></name>
<etal/>
</person-group><article-title>Distinguishing features of long COVID identified through immune profiling</article-title><source>Nature</source><year>2023</year><volume>623</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06651-y</pub-id><pub-id pub-id-type="pmid">37748514</pub-id>
</element-citation></ref><ref id="B19-idr-17-00056"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phetsouphanh</surname><given-names>C.</given-names></name>
<name><surname>Darley</surname><given-names>D.R.</given-names></name>
<name><surname>Wilson</surname><given-names>D.B.</given-names></name>
<name><surname>Howe</surname><given-names>A.</given-names></name>
<name><surname>Munier</surname><given-names>C.M.L.</given-names></name>
<name><surname>Patel</surname><given-names>S.K.</given-names></name>
<name><surname>Juno</surname><given-names>J.A.</given-names></name>
<name><surname>Burrell</surname><given-names>L.M.</given-names></name>
<name><surname>Kent</surname><given-names>S.J.</given-names></name>
<name><surname>Dore</surname><given-names>G.J.</given-names></name>
<etal/>
</person-group><article-title>Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01113-x</pub-id><pub-id pub-id-type="pmid">35027728</pub-id>
</element-citation></ref><ref id="B20-idr-17-00056"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>D.G.</given-names></name>
<name><surname>Ng</surname><given-names>R.H.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Choi</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Hong</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Multiple early factors anticipate post-acute COVID-19 sequelae</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>881</fpage><lpage>895.e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.014</pub-id><pub-id pub-id-type="pmid">35216672</pub-id>
</element-citation></ref><ref id="B21-idr-17-00056"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peluso</surname><given-names>M.J.</given-names></name>
<name><surname>Deveau</surname><given-names>T.M.</given-names></name>
<name><surname>Munter</surname><given-names>S.E.</given-names></name>
<name><surname>Ryder</surname><given-names>D.</given-names></name>
<name><surname>Buck</surname><given-names>A.</given-names></name>
<name><surname>Beck-Engeser</surname><given-names>G.</given-names></name>
<name><surname>Chan</surname><given-names>F.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>Goldberg</surname><given-names>S.A.</given-names></name>
<name><surname>Hoh</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Chronic viral coinfections differentially affect the likelihood of developing long COVID</article-title><source>J. Clin. Investig.</source><year>2023</year><volume>133</volume><fpage>e163669</fpage><pub-id pub-id-type="doi">10.1172/JCI163669</pub-id><pub-id pub-id-type="pmid">36454631</pub-id>
</element-citation></ref><ref id="B22-idr-17-00056"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pretorius</surname><given-names>E.</given-names></name>
<name><surname>Vlok</surname><given-names>M.</given-names></name>
<name><surname>Venter</surname><given-names>C.</given-names></name>
<name><surname>Bezuidenhout</surname><given-names>J.A.</given-names></name>
<name><surname>Laubscher</surname><given-names>G.J.</given-names></name>
<name><surname>Steenkamp</surname><given-names>J.</given-names></name>
<name><surname>Kell</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin</article-title><source>Cardiovasc. Diabetol.</source><year>2021</year><volume>20</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1186/s12933-021-01359-7</pub-id><pub-id pub-id-type="pmid">34425843</pub-id>
</element-citation></ref><ref id="B23-idr-17-00056"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meinhardt</surname><given-names>J.</given-names></name>
<name><surname>Radke</surname><given-names>J.</given-names></name>
<name><surname>Dittmayer</surname><given-names>C.</given-names></name>
<name><surname>Franz</surname><given-names>J.</given-names></name>
<name><surname>Thomas</surname><given-names>C.</given-names></name>
<name><surname>Mothes</surname><given-names>R.</given-names></name>
<name><surname>Laue</surname><given-names>M.</given-names></name>
<name><surname>Schneider</surname><given-names>J.</given-names></name>
<name><surname>Brunink</surname><given-names>S.</given-names></name>
<name><surname>Greuel</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19</article-title><source>Nat. Neurosci.</source><year>2021</year><volume>24</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-00758-5</pub-id><pub-id pub-id-type="pmid">33257876</pub-id>
</element-citation></ref><ref id="B24-idr-17-00056"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarubbo</surname><given-names>F.</given-names></name>
<name><surname>El Haji</surname><given-names>K.</given-names></name>
<name><surname>Vidal-Balle</surname><given-names>A.</given-names></name>
<name><surname>Bargay Lleonart</surname><given-names>J.</given-names></name>
</person-group><article-title>Neurological consequences of COVID-19 and brain related pathogenic mechanisms: A new challenge for neuroscience</article-title><source>Brain Behav. Immun. Health</source><year>2022</year><volume>19</volume><fpage>100399</fpage><pub-id pub-id-type="doi">10.1016/j.bbih.2021.100399</pub-id><pub-id pub-id-type="pmid">34870247</pub-id>
</element-citation></ref><ref id="B25-idr-17-00056"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Putrino</surname><given-names>D.</given-names></name>
<name><surname>Woodcock</surname><given-names>A.</given-names></name>
<name><surname>Kell</surname><given-names>D.B.</given-names></name>
<name><surname>Pretorius</surname><given-names>E.</given-names></name>
</person-group><article-title>Long COVID: Pathophysiological factors and abnormalities of coagulation</article-title><source>Trends Endocrinol. Metab.</source><year>2023</year><volume>34</volume><fpage>321</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2023.03.002</pub-id><pub-id pub-id-type="pmid">37080828</pub-id>
</element-citation></ref><ref id="B26-idr-17-00056"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Mak</surname><given-names>J.W.Y.</given-names></name>
<name><surname>Su</surname><given-names>Q.</given-names></name>
<name><surname>Yeoh</surname><given-names>Y.K.</given-names></name>
<name><surname>Lui</surname><given-names>G.C.</given-names></name>
<name><surname>Ng</surname><given-names>S.S.S.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>A.Y.L.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Hui</surname><given-names>D.S.</given-names></name>
<etal/>
</person-group><article-title>Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-325989</pub-id><pub-id pub-id-type="pmid">35082169</pub-id>
</element-citation></ref><ref id="B27-idr-17-00056"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zollner</surname><given-names>A.</given-names></name>
<name><surname>Koch</surname><given-names>R.</given-names></name>
<name><surname>Jukic</surname><given-names>A.</given-names></name>
<name><surname>Pfister</surname><given-names>A.</given-names></name>
<name><surname>Meyer</surname><given-names>M.</given-names></name>
<name><surname>Rossler</surname><given-names>A.</given-names></name>
<name><surname>Kimpel</surname><given-names>J.</given-names></name>
<name><surname>Adolph</surname><given-names>T.E.</given-names></name>
<name><surname>Tilg</surname><given-names>H.</given-names></name>
</person-group><article-title>Postacute COVID-19 Is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases</article-title><source>Gastroenterology</source><year>2022</year><volume>163</volume><fpage>495</fpage><lpage>506.e8</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2022.04.037</pub-id><pub-id pub-id-type="pmid">35508284</pub-id>
</element-citation></ref><ref id="B28-idr-17-00056"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zuo</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Lui</surname><given-names>G.C.Y.</given-names></name>
<name><surname>Yeoh</surname><given-names>Y.K.</given-names></name>
<name><surname>Li</surname><given-names>A.Y.L.</given-names></name>
<name><surname>Zhan</surname><given-names>H.</given-names></name>
<name><surname>Wan</surname><given-names>Y.</given-names></name>
<name><surname>Chung</surname><given-names>A.C.K.</given-names></name>
<name><surname>Cheung</surname><given-names>C.P.</given-names></name>
<name><surname>Chen</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Alterations in Gut Microbiota of Patients with COVID-19 During Time of Hospitalization</article-title><source>Gastroenterology</source><year>2020</year><volume>159</volume><fpage>944</fpage><lpage>955.e8</lpage><page-range>944&#x02013;955.e8</page-range><pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.048</pub-id><pub-id pub-id-type="pmid">32442562</pub-id>
</element-citation></ref><ref id="B29-idr-17-00056"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendes de Almeida</surname><given-names>V.</given-names></name>
<name><surname>Engel</surname><given-names>D.F.</given-names></name>
<name><surname>Ricci</surname><given-names>M.F.</given-names></name>
<name><surname>Cruz</surname><given-names>C.S.</given-names></name>
<name><surname>Lopes</surname><given-names>I.S.</given-names></name>
<name><surname>Alves</surname><given-names>D.A.</given-names></name>
<name><surname>d&#x02019;Auriol</surname><given-names>M.</given-names></name>
<name><surname>Magalhaes</surname><given-names>J.</given-names></name>
<name><surname>Machado</surname><given-names>E.C.</given-names></name>
<name><surname>Rocha</surname><given-names>V.M.</given-names></name>
<etal/>
</person-group><article-title>Gut microbiota from patients with COVID-19 cause alterations in mice that resemble post-COVID symptoms</article-title><source>Gut Microbes</source><year>2023</year><volume>15</volume><fpage>2249146</fpage><pub-id pub-id-type="doi">10.1080/19490976.2023.2249146</pub-id><pub-id pub-id-type="pmid">37668317</pub-id>
</element-citation></ref><ref id="B30-idr-17-00056"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asadi-Pooya</surname><given-names>A.A.</given-names></name>
<name><surname>Akbari</surname><given-names>A.</given-names></name>
<name><surname>Emami</surname><given-names>A.</given-names></name>
<name><surname>Lotfi</surname><given-names>M.</given-names></name>
<name><surname>Rostamihosseinkhani</surname><given-names>M.</given-names></name>
<name><surname>Nemati</surname><given-names>H.</given-names></name>
<name><surname>Barzegar</surname><given-names>Z.</given-names></name>
<name><surname>Kabiri</surname><given-names>M.</given-names></name>
<name><surname>Zeraatpisheh</surname><given-names>Z.</given-names></name>
<name><surname>Farjoud-Kouhanjani</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Risk Factors Associated with Long COVID Syndrome: A Retrospective Study</article-title><source>Iran. J. Med. Sci.</source><year>2021</year><volume>46</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">34840383</pub-id>
</element-citation></ref><ref id="B31-idr-17-00056"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Tomasoni</surname><given-names>D.</given-names></name>
<name><surname>Falcinella</surname><given-names>C.</given-names></name>
<name><surname>Barbanotti</surname><given-names>D.</given-names></name>
<name><surname>Castoldi</surname><given-names>R.</given-names></name>
<name><surname>Mule</surname><given-names>G.</given-names></name>
<name><surname>Augello</surname><given-names>M.</given-names></name>
<name><surname>Mondatore</surname><given-names>D.</given-names></name>
<name><surname>Allegrini</surname><given-names>M.</given-names></name>
<name><surname>Cona</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Female gender is associated with long COVID syndrome: A prospective cohort study</article-title><source>Clin. Microbiol. Infect.</source><year>2022</year><volume>28</volume><fpage>611.e9</fpage><lpage>611.e16</lpage><page-range>611.e9&#x02013;611.e16</page-range><pub-id pub-id-type="doi">10.1016/j.cmi.2021.11.002</pub-id></element-citation></ref><ref id="B32-idr-17-00056"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandez-de-Las-Penas</surname><given-names>C.</given-names></name>
<name><surname>Martin-Guerrero</surname><given-names>J.D.</given-names></name>
<name><surname>Pellicer-Valero</surname><given-names>O.J.</given-names></name>
<name><surname>Navarro-Pardo</surname><given-names>E.</given-names></name>
<name><surname>Gomez-Mayordomo</surname><given-names>V.</given-names></name>
<name><surname>Cuadrado</surname><given-names>M.L.</given-names></name>
<name><surname>Arias-Navalon</surname><given-names>J.A.</given-names></name>
<name><surname>Cigaran-Mendez</surname><given-names>M.</given-names></name>
<name><surname>Hernandez-Barrera</surname><given-names>V.</given-names></name>
<name><surname>Arendt-Nielsen</surname><given-names>L.</given-names></name>
</person-group><article-title>Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>413</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11020413</pub-id><pub-id pub-id-type="pmid">35054108</pub-id>
</element-citation></ref><ref id="B33-idr-17-00056"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Townsend</surname><given-names>L.</given-names></name>
<name><surname>Dyer</surname><given-names>A.H.</given-names></name>
<name><surname>Jones</surname><given-names>K.</given-names></name>
<name><surname>Dunne</surname><given-names>J.</given-names></name>
<name><surname>Mooney</surname><given-names>A.</given-names></name>
<name><surname>Gaffney</surname><given-names>F.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>L.</given-names></name>
<name><surname>Leavy</surname><given-names>D.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>K.</given-names></name>
<name><surname>Dowds</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0240784</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0240784</pub-id><pub-id pub-id-type="pmid">33166287</pub-id>
</element-citation></ref><ref id="B34-idr-17-00056"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gagliardi</surname><given-names>M.C.</given-names></name>
<name><surname>Tieri</surname><given-names>P.</given-names></name>
<name><surname>Ortona</surname><given-names>E.</given-names></name>
<name><surname>Ruggieri</surname><given-names>A.</given-names></name>
</person-group><article-title>ACE2 expression and sex disparity in COVID-19</article-title><source>Cell Death Discov.</source><year>2020</year><volume>6</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1038/s41420-020-0276-1</pub-id><pub-id pub-id-type="pmid">32499922</pub-id>
</element-citation></ref><ref id="B35-idr-17-00056"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forster</surname><given-names>C.</given-names></name>
<name><surname>Colombo</surname><given-names>M.G.</given-names></name>
<name><surname>Wetzel</surname><given-names>A.J.</given-names></name>
<name><surname>Martus</surname><given-names>P.</given-names></name>
<name><surname>Joos</surname><given-names>S.</given-names></name>
</person-group><article-title>Persisting Symptoms After COVID-19</article-title><source>Dtsch. Arztebl. Int.</source><year>2022</year><volume>119</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.3238/arztebl.m2022.0147</pub-id><pub-id pub-id-type="pmid">35236547</pub-id>
</element-citation></ref><ref id="B36-idr-17-00056"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guzman-Esquivel</surname><given-names>J.</given-names></name>
<name><surname>Mendoza-Hernandez</surname><given-names>M.A.</given-names></name>
<name><surname>Guzman-Solorzano</surname><given-names>H.P.</given-names></name>
<name><surname>Sarmiento-Hernandez</surname><given-names>K.A.</given-names></name>
<name><surname>Rodriguez-Sanchez</surname><given-names>I.P.</given-names></name>
<name><surname>Martinez-Fierro</surname><given-names>M.L.</given-names></name>
<name><surname>Paz-Michel</surname><given-names>B.A.</given-names></name>
<name><surname>Murillo-Zamora</surname><given-names>E.</given-names></name>
<name><surname>Rojas-Larios</surname><given-names>F.</given-names></name>
<name><surname>Lugo-Trampe</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Clinical Characteristics in the Acute Phase of COVID-19 That Predict Long COVID: Tachycardia, Myalgias, Severity, and Use of Antibiotics as Main Risk Factors, While Education and Blood Group B Are Protective</article-title><source>Healthcare</source><year>2023</year><volume>11</volume><elocation-id>197</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare11020197</pub-id><pub-id pub-id-type="pmid">36673565</pub-id>
</element-citation></ref><ref id="B37-idr-17-00056"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sudre</surname><given-names>C.H.</given-names></name>
<name><surname>Murray</surname><given-names>B.</given-names></name>
<name><surname>Varsavsky</surname><given-names>T.</given-names></name>
<name><surname>Graham</surname><given-names>M.S.</given-names></name>
<name><surname>Penfold</surname><given-names>R.S.</given-names></name>
<name><surname>Bowyer</surname><given-names>R.C.</given-names></name>
<name><surname>Pujol</surname><given-names>J.C.</given-names></name>
<name><surname>Klaser</surname><given-names>K.</given-names></name>
<name><surname>Antonelli</surname><given-names>M.</given-names></name>
<name><surname>Canas</surname><given-names>L.S.</given-names></name>
<etal/>
</person-group><article-title>Attributes and predictors of long COVID</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>626</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01292-y</pub-id><pub-id pub-id-type="pmid">33692530</pub-id>
</element-citation></ref><ref id="B38-idr-17-00056"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho-Schneider</surname><given-names>C.</given-names></name>
<name><surname>Laurent</surname><given-names>E.</given-names></name>
<name><surname>Lemaignen</surname><given-names>A.</given-names></name>
<name><surname>Beaufils</surname><given-names>E.</given-names></name>
<name><surname>Bourbao-Tournois</surname><given-names>C.</given-names></name>
<name><surname>Laribi</surname><given-names>S.</given-names></name>
<name><surname>Flament</surname><given-names>T.</given-names></name>
<name><surname>Ferreira-Maldent</surname><given-names>N.</given-names></name>
<name><surname>Bruyere</surname><given-names>F.</given-names></name>
<name><surname>Stefic</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Follow-up of adults with noncritical COVID-19 two months after symptom onset</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><fpage>258</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.09.052</pub-id><pub-id pub-id-type="pmid">33031948</pub-id>
</element-citation></ref><ref id="B39-idr-17-00056"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vimercati</surname><given-names>L.</given-names></name>
<name><surname>De Maria</surname><given-names>L.</given-names></name>
<name><surname>Quarato</surname><given-names>M.</given-names></name>
<name><surname>Caputi</surname><given-names>A.</given-names></name>
<name><surname>Gesualdo</surname><given-names>L.</given-names></name>
<name><surname>Migliore</surname><given-names>G.</given-names></name>
<name><surname>Cavone</surname><given-names>D.</given-names></name>
<name><surname>Sponselli</surname><given-names>S.</given-names></name>
<name><surname>Pipoli</surname><given-names>A.</given-names></name>
<name><surname>Inchingolo</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Association Between Long COVID and Overweight/Obesity</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>4143</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10184143</pub-id><pub-id pub-id-type="pmid">34575251</pub-id>
</element-citation></ref><ref id="B40-idr-17-00056"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quan</surname><given-names>S.F.</given-names></name>
<name><surname>Weaver</surname><given-names>M.D.</given-names></name>
<name><surname>Czeisler</surname><given-names>M.E.</given-names></name>
<name><surname>Barger</surname><given-names>L.K.</given-names></name>
<name><surname>Booker</surname><given-names>L.A.</given-names></name>
<name><surname>Howard</surname><given-names>M.E.</given-names></name>
<name><surname>Jackson</surname><given-names>M.L.</given-names></name>
<name><surname>Lane</surname><given-names>R.I.</given-names></name>
<name><surname>McDonald</surname><given-names>C.F.</given-names></name>
<name><surname>Ridgers</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Association of Obstructive Sleep Apnea with Post-Acute Sequelae of SARS-CoV-2 Infection</article-title><source>Am. J. Med.</source><year>2024</year><volume>137</volume><fpage>529</fpage><lpage>537.e3</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2024.02.023</pub-id><pub-id pub-id-type="pmid">38401674</pub-id>
</element-citation></ref><ref id="B41-idr-17-00056"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Quan</surname><given-names>L.</given-names></name>
<name><surname>Chavarro</surname><given-names>J.E.</given-names></name>
<name><surname>Slopen</surname><given-names>N.</given-names></name>
<name><surname>Kubzansky</surname><given-names>L.D.</given-names></name>
<name><surname>Koenen</surname><given-names>K.C.</given-names></name>
<name><surname>Kang</surname><given-names>J.H.</given-names></name>
<name><surname>Weisskopf</surname><given-names>M.G.</given-names></name>
<name><surname>Branch-Elliman</surname><given-names>W.</given-names></name>
<name><surname>Roberts</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection with Risk of Post-COVID-19 Conditions</article-title><source>JAMA Psychiatry</source><year>2022</year><volume>79</volume><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.2640</pub-id><pub-id pub-id-type="pmid">36069885</pub-id>
</element-citation></ref><ref id="B42-idr-17-00056"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation></ref><ref id="B43-idr-17-00056"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abu Hamdh</surname><given-names>B.</given-names></name>
<name><surname>Nazzal</surname><given-names>Z.</given-names></name>
</person-group><article-title>A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>4896</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-30583-2</pub-id><pub-id pub-id-type="pmid">36966161</pub-id>
</element-citation></ref><ref id="B44-idr-17-00056"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayoubkhani</surname><given-names>D.</given-names></name>
<name><surname>Bermingham</surname><given-names>C.</given-names></name>
<name><surname>Pouwels</surname><given-names>K.B.</given-names></name>
<name><surname>Glickman</surname><given-names>M.</given-names></name>
<name><surname>Nafilyan</surname><given-names>V.</given-names></name>
<name><surname>Zaccardi</surname><given-names>F.</given-names></name>
<name><surname>Khunti</surname><given-names>K.</given-names></name>
<name><surname>Alwan</surname><given-names>N.A.</given-names></name>
<name><surname>Walker</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Trajectory of long covid symptoms after COVID-19 vaccination: Community based cohort study</article-title><source>BMJ</source><year>2022</year><volume>377</volume><fpage>e069676</fpage><pub-id pub-id-type="doi">10.1136/bmj-2021-069676</pub-id><pub-id pub-id-type="pmid">35584816</pub-id>
</element-citation></ref><ref id="B45-idr-17-00056"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babicki</surname><given-names>M.</given-names></name>
<name><surname>Kapusta</surname><given-names>J.</given-names></name>
<name><surname>Pieniawska-&#x0015a;miech</surname><given-names>K.</given-names></name>
<name><surname>Ka&#x00142;uzi&#x00144;ska-Ko&#x00142;at</surname><given-names>&#x0017b;.</given-names></name>
<name><surname>Ko&#x00142;at</surname><given-names>D.</given-names></name>
<name><surname>Mastalerz-Migas</surname><given-names>A.</given-names></name>
<name><surname>Jankowski</surname><given-names>P.</given-names></name>
<name><surname>Chudzik</surname><given-names>M.</given-names></name>
</person-group><article-title>Do COVID-19 Vaccinations Affect the Most Common Post-COVID Symptoms? Initial Data from the STOP-COVID Register-12-Month Follow-Up</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1370</elocation-id><pub-id pub-id-type="doi">10.3390/v15061370</pub-id><pub-id pub-id-type="pmid">37376668</pub-id>
</element-citation></ref><ref id="B46-idr-17-00056"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertuccio</surname><given-names>P.</given-names></name>
<name><surname>Degli Antoni</surname><given-names>M.</given-names></name>
<name><surname>Minisci</surname><given-names>D.</given-names></name>
<name><surname>Amadasi</surname><given-names>S.</given-names></name>
<name><surname>Castelli</surname><given-names>F.</given-names></name>
<name><surname>Odone</surname><given-names>A.</given-names></name>
<name><surname>Quiros-Roldan</surname><given-names>E.</given-names></name>
</person-group><article-title>The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: A retrospective study</article-title><source>Infection</source><year>2023</year><volume>51</volume><fpage>1633</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1007/s15010-023-02028-5</pub-id><pub-id pub-id-type="pmid">37024626</pub-id>
</element-citation></ref><ref id="B47-idr-17-00056"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bramante</surname><given-names>C.T.</given-names></name>
<name><surname>Buse</surname><given-names>J.B.</given-names></name>
<name><surname>Liebovitz</surname><given-names>D.</given-names></name>
<name><surname>Nicklas</surname><given-names>J.</given-names></name>
<name><surname>Puskarich</surname><given-names>M.A.</given-names></name>
<name><surname>Cohen</surname><given-names>K.</given-names></name>
<name><surname>Belani</surname><given-names>H.</given-names></name>
<name><surname>Anderson</surname><given-names>B.</given-names></name>
<name><surname>Huling</surname><given-names>J.D.</given-names></name>
<name><surname>Tignanelli</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Outpatient treatment of COVID-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up</article-title><source>medRxiv</source><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.12.21.22283753</pub-id></element-citation></ref><ref id="B48-idr-17-00056"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brunvoll</surname><given-names>S.H.</given-names></name>
<name><surname>Nygaard</surname><given-names>A.B.</given-names></name>
<name><surname>Fagerland</surname><given-names>M.W.</given-names></name>
<name><surname>Holland</surname><given-names>P.</given-names></name>
<name><surname>Ellingjord-Dale</surname><given-names>M.</given-names></name>
<name><surname>Dahl</surname><given-names>J.A.</given-names></name>
<name><surname>Soraas</surname><given-names>A.</given-names></name>
</person-group><article-title>Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection</article-title><source>Int. J. Infect. Dis.</source><year>2023</year><volume>126</volume><fpage>10</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2022.11.009</pub-id><pub-id pub-id-type="pmid">36375693</pub-id>
</element-citation></ref><ref id="B49-idr-17-00056"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Catal&#x000e0;</surname><given-names>M.</given-names></name>
<name><surname>Mercad&#x000e9;-Besora</surname><given-names>N.</given-names></name>
<name><surname>Kolde</surname><given-names>R.</given-names></name>
<name><surname>Trinh</surname><given-names>N.T.H.</given-names></name>
<name><surname>Roel</surname><given-names>E.</given-names></name>
<name><surname>Burn</surname><given-names>E.</given-names></name>
<name><surname>Rathod-Mistry</surname><given-names>T.</given-names></name>
<name><surname>Kostka</surname><given-names>K.</given-names></name>
<name><surname>Man</surname><given-names>W.Y.</given-names></name>
<name><surname>Delmestri</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: Staggered cohort study of data from the UK, Spain, and Estonia</article-title><source>Lancet Respir. Med.</source><year>2024</year><volume>12</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(23)00414-9</pub-id><pub-id pub-id-type="pmid">38219763</pub-id>
</element-citation></ref><ref id="B50-idr-17-00056"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Catal&#x000e1;n</surname><given-names>I.P.</given-names></name>
<name><surname>Mart&#x000ed;</surname><given-names>C.R.</given-names></name>
<name><surname>Sota</surname><given-names>D.P.</given-names></name>
<name><surname>&#x000c1;lvarez</surname><given-names>A.C.</given-names></name>
<name><surname>Gimeno</surname><given-names>M.J.E.</given-names></name>
<name><surname>Juana</surname><given-names>S.F.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>G.H.</given-names></name>
<name><surname>Bajo</surname><given-names>E.D.</given-names></name>
<name><surname>Gaya</surname><given-names>N.T.</given-names></name>
<name><surname>Blasco</surname><given-names>J.U.</given-names></name>
<etal/>
</person-group><article-title>Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1002/jmv.27296</pub-id><pub-id pub-id-type="pmid">34436783</pub-id>
</element-citation></ref><ref id="B51-idr-17-00056"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Congdon</surname><given-names>S.</given-names></name>
<name><surname>Narrowe</surname><given-names>Z.</given-names></name>
<name><surname>Yone</surname><given-names>N.</given-names></name>
<name><surname>Gunn</surname><given-names>J.</given-names></name>
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Nori</surname><given-names>P.</given-names></name>
<name><surname>Cowman</surname><given-names>K.</given-names></name>
<name><surname>Islam</surname><given-names>M.</given-names></name>
<name><surname>Rikin</surname><given-names>S.</given-names></name>
<name><surname>Starrels</surname><given-names>J.</given-names></name>
</person-group><article-title>Nirmatrelvir/ritonavir and risk of long COVID symptoms: A retrospective cohort study</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>19688</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-46912-4</pub-id><pub-id pub-id-type="pmid">37951998</pub-id>
</element-citation></ref><ref id="B52-idr-17-00056"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davelaar</surname><given-names>J.</given-names></name>
<name><surname>Jessurun</surname><given-names>N.</given-names></name>
<name><surname>Schaap</surname><given-names>G.</given-names></name>
<name><surname>Bode</surname><given-names>C.</given-names></name>
<name><surname>Vonkeman</surname><given-names>H.</given-names></name>
</person-group><article-title>The effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge: A retrospective follow up study</article-title><source>Clin. Exp. Med.</source><year>2023</year><volume>23</volume><fpage>4881</fpage><lpage>4888</lpage><pub-id pub-id-type="doi">10.1007/s10238-023-01153-7</pub-id><pub-id pub-id-type="pmid">37552413</pub-id>
</element-citation></ref><ref id="B53-idr-17-00056"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Durstenfeld</surname><given-names>M.S.</given-names></name>
<name><surname>Peluso</surname><given-names>M.J.</given-names></name>
<name><surname>Lin</surname><given-names>F.</given-names></name>
<name><surname>Peyser</surname><given-names>N.D.</given-names></name>
<name><surname>Isasi</surname><given-names>C.</given-names></name>
<name><surname>Carton</surname><given-names>T.W.</given-names></name>
<name><surname>Henrich</surname><given-names>T.J.</given-names></name>
<name><surname>Deeks</surname><given-names>S.G.</given-names></name>
<name><surname>Olgin</surname><given-names>J.E.</given-names></name>
<name><surname>Pletcher</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study</article-title><source>J. Med. Virol.</source><year>2024</year><volume>96</volume><fpage>e29333</fpage><pub-id pub-id-type="doi">10.1002/jmv.29333</pub-id><pub-id pub-id-type="pmid">38175151</pub-id>
</element-citation></ref><ref id="B54-idr-17-00056"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fatima</surname><given-names>S.</given-names></name>
<name><surname>Ismail</surname><given-names>M.</given-names></name>
<name><surname>Ejaz</surname><given-names>T.</given-names></name>
<name><surname>Shah</surname><given-names>Z.</given-names></name>
<name><surname>Fatima</surname><given-names>S.</given-names></name>
<name><surname>Shahzaib</surname><given-names>M.</given-names></name>
<name><surname>Jafri</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Association between long COVID and vaccination: A 12-month follow-up study in a low- to middle-income country</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0294780</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0294780</pub-id><pub-id pub-id-type="pmid">37992084</pub-id>
</element-citation></ref><ref id="B55-idr-17-00056"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandez-de-Las-Penas</surname><given-names>C.</given-names></name>
<name><surname>Franco-Moreno</surname><given-names>A.</given-names></name>
<name><surname>Ruiz-Ruigomez</surname><given-names>M.</given-names></name>
<name><surname>Arrieta-Ortubay</surname><given-names>E.</given-names></name>
<name><surname>Ryan-Murua</surname><given-names>P.</given-names></name>
<name><surname>Lumbreras-Bermejo</surname><given-names>C.</given-names></name>
<name><surname>Del-Valle-Loarte</surname><given-names>P.</given-names></name>
<name><surname>Pellicer-Valero</surname><given-names>O.J.</given-names></name>
<name><surname>Giordano</surname><given-names>R.</given-names></name>
<name><surname>Arendt-Nielsen</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>947</elocation-id><pub-id pub-id-type="doi">10.3390/v16060947</pub-id><pub-id pub-id-type="pmid">38932239</pub-id>
</element-citation></ref><ref id="B56-idr-17-00056"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gebo</surname><given-names>K.A.</given-names></name>
<name><surname>Heath</surname><given-names>S.L.</given-names></name>
<name><surname>Fukuta</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Baksh</surname><given-names>S.</given-names></name>
<name><surname>Abraham</surname><given-names>A.G.</given-names></name>
<name><surname>Habtehyimer</surname><given-names>F.</given-names></name>
<name><surname>Shade</surname><given-names>D.</given-names></name>
<name><surname>Ruff</surname><given-names>J.</given-names></name>
<name><surname>Ram</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Early antibody treatment, inflammation, and risk of post-COVID conditions</article-title><source>mBio</source><year>2023</year><volume>14</volume><elocation-id>e0061823</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.00618-23</pub-id><pub-id pub-id-type="pmid">37724870</pub-id>
</element-citation></ref><ref id="B57-idr-17-00056"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>H.T.</given-names></name>
<name><surname>Wong</surname><given-names>H.K.</given-names></name>
<name><surname>Lyu</surname><given-names>A.</given-names></name>
<name><surname>Cheung</surname><given-names>C.H.</given-names></name>
<name><surname>Bian</surname><given-names>Z.</given-names></name>
</person-group><article-title>Prevalence and risk factors of long COVID 6&#x02013;12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e28862</fpage><pub-id pub-id-type="doi">10.1002/jmv.28862</pub-id><pub-id pub-id-type="pmid">37334978</pub-id>
</element-citation></ref><ref id="B58-idr-17-00056"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>MacCallum-Bridges</surname><given-names>C.</given-names></name>
<name><surname>Hirschtick</surname><given-names>J.L.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
<name><surname>Orellana</surname><given-names>R.C.</given-names></name>
<name><surname>Elliott</surname><given-names>M.R.</given-names></name>
<name><surname>Fleischer</surname><given-names>N.L.</given-names></name>
</person-group><article-title>The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020&#x02013;2022</article-title><source>Ann. Epidemiol.</source><year>2024</year><volume>92</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2024.02.007</pub-id><pub-id pub-id-type="pmid">38382771</pub-id>
</element-citation></ref><ref id="B59-idr-17-00056"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nehme</surname><given-names>M.</given-names></name>
<name><surname>Vetter</surname><given-names>P.</given-names></name>
<name><surname>Chappuis</surname><given-names>F.</given-names></name>
<name><surname>Kaiser</surname><given-names>L.</given-names></name>
<name><surname>Guessous</surname><given-names>I.</given-names></name>
<name><surname>CoviCare Study</surname><given-names>T.</given-names></name>
</person-group><article-title>Prevalence of Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared with Negative Controls and Association with Vaccination Status</article-title><source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source><year>2023</year><volume>76</volume><fpage>1567</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac947</pub-id></element-citation></ref><ref id="B60-idr-17-00056"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nevalainen</surname><given-names>O.P.O.</given-names></name>
<name><surname>Horstia</surname><given-names>S.</given-names></name>
<name><surname>Laakkonen</surname><given-names>S.</given-names></name>
<name><surname>Rutanen</surname><given-names>J.</given-names></name>
<name><surname>Mustonen</surname><given-names>J.M.J.</given-names></name>
<name><surname>Kalliala</surname><given-names>I.E.J.</given-names></name>
<name><surname>Ansakorpi</surname><given-names>H.</given-names></name>
<name><surname>Kreivi</surname><given-names>H.R.</given-names></name>
<name><surname>Kuutti</surname><given-names>P.</given-names></name>
<name><surname>Paajanen</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>6152</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-33825-5</pub-id><pub-id pub-id-type="pmid">36257950</pub-id>
</element-citation></ref><ref id="B61-idr-17-00056"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trinh</surname><given-names>N.T.</given-names></name>
<name><surname>J&#x000f6;dicke</surname><given-names>A.M.</given-names></name>
<name><surname>Catal&#x000e0;</surname><given-names>M.</given-names></name>
<name><surname>Mercad&#x000e9;-Besora</surname><given-names>N.</given-names></name>
<name><surname>Hayati</surname><given-names>S.</given-names></name>
<name><surname>Lupattelli</surname><given-names>A.</given-names></name>
<name><surname>Prieto-Alhambra</surname><given-names>D.</given-names></name>
<name><surname>Nordeng</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Effectiveness of COVID-19 vaccines to prevent long COVID: Data from Norway</article-title><source>Lancet Respir. Med.</source><year>2024</year><volume>12</volume><fpage>e33</fpage><lpage>e34</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(24)00082-1</pub-id><pub-id pub-id-type="pmid">38614106</pub-id>
</element-citation></ref><ref id="B62-idr-17-00056"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>Xiao</surname><given-names>W.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Jia</surname><given-names>Q.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
</person-group><article-title>Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e29014</fpage><pub-id pub-id-type="doi">10.1002/jmv.29014</pub-id><pub-id pub-id-type="pmid">37522243</pub-id>
</element-citation></ref><ref id="B63-idr-17-00056"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woldegiorgis</surname><given-names>M.</given-names></name>
<name><surname>Cadby</surname><given-names>G.</given-names></name>
<name><surname>Ngeh</surname><given-names>S.</given-names></name>
<name><surname>Korda</surname><given-names>R.J.</given-names></name>
<name><surname>Armstrong</surname><given-names>P.K.</given-names></name>
<name><surname>Maticevic</surname><given-names>J.</given-names></name>
<name><surname>Knight</surname><given-names>P.</given-names></name>
<name><surname>Jardine</surname><given-names>A.</given-names></name>
<name><surname>Bloomfield</surname><given-names>L.E.</given-names></name>
<name><surname>Effler</surname><given-names>P.V.</given-names></name>
</person-group><article-title>Long COVID in a highly vaccinated but largely unexposed Australian population following the 2022 SARS-CoV-2 Omicron wave: A cross-sectional survey</article-title><source>Med. J. Aust.</source><year>2024</year><volume>220</volume><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.5694/mja2.52256</pub-id><pub-id pub-id-type="pmid">38508863</pub-id>
</element-citation></ref><ref id="B64-idr-17-00056"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Stallings-Smith</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Case</surname><given-names>S.</given-names></name>
<name><surname>Hong</surname><given-names>Y.R.</given-names></name>
</person-group><article-title>COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>3529</fpage><lpage>3535</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.04.070</pub-id><pub-id pub-id-type="pmid">38670844</pub-id>
</element-citation></ref><ref id="B65-idr-17-00056"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Goldfeld</surname><given-names>K.S.</given-names></name>
<name><surname>Cobb</surname><given-names>G.F.</given-names></name>
<name><surname>Sturm-Reganato</surname><given-names>C.L.</given-names></name>
<name><surname>Ostrosky-Zeichner</surname><given-names>L.</given-names></name>
<name><surname>Jayaweera</surname><given-names>D.T.</given-names></name>
<name><surname>Philley</surname><given-names>J.V.</given-names></name>
<name><surname>Desruisseaux</surname><given-names>M.S.</given-names></name>
<name><surname>Keller</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Convalescent Plasma Therapy: Long-Term Implications</article-title><source>Open Forum Infect. Dis.</source><year>2024</year><volume>11</volume><fpage>ofad686</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad686</pub-id><pub-id pub-id-type="pmid">38269049</pub-id>
</element-citation></ref><ref id="B66-idr-17-00056"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antonelli</surname><given-names>M.</given-names></name>
<name><surname>Penfold</surname><given-names>R.S.</given-names></name>
<name><surname>Canas</surname><given-names>L.D.S.</given-names></name>
<name><surname>Sudre</surname><given-names>C.</given-names></name>
<name><surname>Rjoob</surname><given-names>K.</given-names></name>
<name><surname>Murray</surname><given-names>B.</given-names></name>
<name><surname>Molteni</surname><given-names>E.</given-names></name>
<name><surname>Kerfoot</surname><given-names>E.</given-names></name>
<name><surname>Cheetham</surname><given-names>N.</given-names></name>
<name><surname>Pujol</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study</article-title><source>J. Infect.</source><year>2023</year><volume>87</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2023.08.009</pub-id><pub-id pub-id-type="pmid">37777159</pub-id>
</element-citation></ref><ref id="B67-idr-17-00056"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richard</surname><given-names>S.A.</given-names></name>
<name><surname>Pollett</surname><given-names>S.D.</given-names></name>
<name><surname>Fries</surname><given-names>A.C.</given-names></name>
<name><surname>Berjohn</surname><given-names>C.M.</given-names></name>
<name><surname>Maves</surname><given-names>R.C.</given-names></name>
<name><surname>Lalani</surname><given-names>T.</given-names></name>
<name><surname>Smith</surname><given-names>A.G.</given-names></name>
<name><surname>Mody</surname><given-names>R.M.</given-names></name>
<name><surname>Ganesan</surname><given-names>A.</given-names></name>
<name><surname>Colombo</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e2251360</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.51360</pub-id><pub-id pub-id-type="pmid">36652247</pub-id>
</element-citation></ref><ref id="B68-idr-17-00056"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nascimento</surname><given-names>T.</given-names></name>
<name><surname>do Valle Costa</surname><given-names>L.</given-names></name>
<name><surname>Ruiz</surname><given-names>A.D.</given-names></name>
<name><surname>Ledo</surname><given-names>C.B.</given-names></name>
<name><surname>Fernandes</surname><given-names>V.P.L.</given-names></name>
<name><surname>Cardoso</surname><given-names>L.F.</given-names></name>
<name><surname>Junior</surname><given-names>J.M.V.</given-names></name>
<name><surname>Saretta</surname><given-names>R.</given-names></name>
<name><surname>Kalil-Filho</surname><given-names>R.</given-names></name>
<name><surname>Drager</surname><given-names>L.F.</given-names></name>
</person-group><article-title>Vaccination status and long COVID symptoms in patients discharged from hospital</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>2481</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-28839-y</pub-id><pub-id pub-id-type="pmid">36774419</pub-id>
</element-citation></ref><ref id="B69-idr-17-00056"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
<name><surname>Bowe</surname><given-names>B.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
</person-group><article-title>Long COVID after breakthrough SARS-CoV-2 infection</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01840-0</pub-id><pub-id pub-id-type="pmid">35614233</pub-id>
</element-citation></ref><ref id="B70-idr-17-00056"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azzolini</surname><given-names>E.</given-names></name>
<name><surname>Levi</surname><given-names>R.</given-names></name>
<name><surname>Sarti</surname><given-names>R.</given-names></name>
<name><surname>Pozzi</surname><given-names>C.</given-names></name>
<name><surname>Mollura</surname><given-names>M.</given-names></name>
<name><surname>Mantovani</surname><given-names>A.</given-names></name>
<name><surname>Rescigno</surname><given-names>M.</given-names></name>
</person-group><article-title>Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.11691</pub-id><pub-id pub-id-type="pmid">35796131</pub-id>
</element-citation></ref><ref id="B71-idr-17-00056"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brannock</surname><given-names>M.D.</given-names></name>
<name><surname>Chew</surname><given-names>R.F.</given-names></name>
<name><surname>Preiss</surname><given-names>A.J.</given-names></name>
<name><surname>Hadley</surname><given-names>E.C.</given-names></name>
<name><surname>Redfield</surname><given-names>S.</given-names></name>
<name><surname>McMurry</surname><given-names>J.A.</given-names></name>
<name><surname>Leese</surname><given-names>P.J.</given-names></name>
<name><surname>Girvin</surname><given-names>A.T.</given-names></name>
<name><surname>Crosskey</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>A.G.</given-names></name>
<etal/>
</person-group><article-title>Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>2914</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38388-7</pub-id><pub-id pub-id-type="pmid">37217471</pub-id>
</element-citation></ref><ref id="B72-idr-17-00056"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Fusco</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Moran</surname><given-names>M.M.</given-names></name>
<name><surname>Coetzer</surname><given-names>H.</given-names></name>
<name><surname>Zamparo</surname><given-names>J.M.</given-names></name>
<name><surname>Alvarez</surname><given-names>M.B.</given-names></name>
<name><surname>Puzniak</surname><given-names>L.</given-names></name>
<name><surname>Tabak</surname><given-names>Y.P.</given-names></name>
<name><surname>Cappelleri</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron</article-title><source>J. Patient Rep. Outcomes</source><year>2023</year><volume>7</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s41687-023-00616-5</pub-id><pub-id pub-id-type="pmid">37486567</pub-id>
</element-citation></ref><ref id="B73-idr-17-00056"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lundberg-Morris</surname><given-names>L.</given-names></name>
<name><surname>Leach</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Martikainen</surname><given-names>J.</given-names></name>
<name><surname>Santosa</surname><given-names>A.</given-names></name>
<name><surname>Gisslen</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Nyberg</surname><given-names>F.</given-names></name>
<name><surname>Bygdell</surname><given-names>M.</given-names></name>
</person-group><article-title>COVID-19 vaccine effectiveness against post-COVID-19 condition among 589,722 individuals in Sweden: Population based cohort study</article-title><source>BMJ</source><year>2023</year><volume>383</volume><fpage>e076990</fpage><pub-id pub-id-type="doi">10.1136/bmj-2023-076990</pub-id><pub-id pub-id-type="pmid">37993131</pub-id>
</element-citation></ref><ref id="B74-idr-17-00056"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malden</surname><given-names>D.E.</given-names></name>
<name><surname>Liu</surname><given-names>I.A.</given-names></name>
<name><surname>Qian</surname><given-names>L.</given-names></name>
<name><surname>Sy</surname><given-names>L.S.</given-names></name>
<name><surname>Lewin</surname><given-names>B.J.</given-names></name>
<name><surname>Asamura</surname><given-names>D.T.</given-names></name>
<name><surname>Ryan</surname><given-names>D.S.</given-names></name>
<name><surname>Bezi</surname><given-names>C.</given-names></name>
<name><surname>Williams</surname><given-names>J.T.B.</given-names></name>
<name><surname>Kaiser</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Post-COVID conditions following COVID-19 vaccination: A retrospective matched cohort study of patients with SARS-CoV-2 infection</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>4101</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-48022-9</pub-id><pub-id pub-id-type="pmid">38778026</pub-id>
</element-citation></ref><ref id="B75-idr-17-00056"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sigler</surname><given-names>R.</given-names></name>
<name><surname>Covarrubias</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Rubarth</surname><given-names>R.B.</given-names></name>
<name><surname>Torosian</surname><given-names>K.</given-names></name>
<name><surname>Sanchez</surname><given-names>C.R.</given-names></name>
<name><surname>Bharti</surname><given-names>A.</given-names></name>
<name><surname>DeGruttola</surname><given-names>V.</given-names></name>
<name><surname>Aslam</surname><given-names>S.</given-names></name>
</person-group><article-title>Post-acute sequelae of COVID-19 in solid organ transplant recipients</article-title><source>Transpl. Infect. Dis.</source><year>2023</year><volume>25</volume><fpage>e14167</fpage><pub-id pub-id-type="doi">10.1111/tid.14167</pub-id><pub-id pub-id-type="pmid">37922371</pub-id>
</element-citation></ref><ref id="B76-idr-17-00056"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tannous</surname><given-names>J.</given-names></name>
<name><surname>Pan</surname><given-names>A.P.</given-names></name>
<name><surname>Potter</surname><given-names>T.</given-names></name>
<name><surname>Bako</surname><given-names>A.T.</given-names></name>
<name><surname>Dlouhy</surname><given-names>K.</given-names></name>
<name><surname>Drews</surname><given-names>A.</given-names></name>
<name><surname>Sostman</surname><given-names>H.D.</given-names></name>
<name><surname>Vahidy</surname><given-names>F.S.</given-names></name>
</person-group><article-title>Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: Analysis of a COVID-19 observational registry for a diverse US metropolitan population</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e067611</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-067611</pub-id></element-citation></ref><ref id="B77-idr-17-00056"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taquet</surname><given-names>M.</given-names></name>
<name><surname>Dercon</surname><given-names>Q.</given-names></name>
<name><surname>Harrison</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections</article-title><source>Brain Behav. Immun.</source><year>2022</year><volume>103</volume><fpage>154</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2022.04.013</pub-id><pub-id pub-id-type="pmid">35447302</pub-id>
</element-citation></ref><ref id="B78-idr-17-00056"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boglione</surname><given-names>L.</given-names></name>
<name><surname>Meli</surname><given-names>G.</given-names></name>
<name><surname>Poletti</surname><given-names>F.</given-names></name>
<name><surname>Rostagno</surname><given-names>R.</given-names></name>
<name><surname>Moglia</surname><given-names>R.</given-names></name>
<name><surname>Cantone</surname><given-names>M.</given-names></name>
<name><surname>Esposito</surname><given-names>M.</given-names></name>
<name><surname>Scianguetta</surname><given-names>C.</given-names></name>
<name><surname>Domenicale</surname><given-names>B.</given-names></name>
<name><surname>Di Pasquale</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Risk factors and incidence of long-COVID syndrome in hospitalized patients: Does remdesivir have a protective effect?</article-title><source>QJM Mon. J. Assoc. Physicians</source><year>2022</year><volume>114</volume><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hcab297</pub-id></element-citation></ref><ref id="B79-idr-17-00056"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fung</surname><given-names>K.W.</given-names></name>
<name><surname>Baye</surname><given-names>F.</given-names></name>
<name><surname>Baik</surname><given-names>S.H.</given-names></name>
<name><surname>McDonald</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients</article-title><source>JAMA Intern. Med.</source><year>2023</year><volume>183</volume><fpage>1404</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2023.5099</pub-id><pub-id pub-id-type="pmid">37870856</pub-id>
</element-citation></ref><ref id="B80-idr-17-00056"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ioannou</surname><given-names>G.N.</given-names></name>
<name><surname>Berry</surname><given-names>K.</given-names></name>
<name><surname>Rajeevan</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Mutalik</surname><given-names>P.</given-names></name>
<name><surname>Yan</surname><given-names>L.</given-names></name>
<name><surname>Bui</surname><given-names>D.</given-names></name>
<name><surname>Cunningham</surname><given-names>F.</given-names></name>
<name><surname>Hynes</surname><given-names>D.M.</given-names></name>
<name><surname>Rowneki</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans: A Target Trial Emulation</article-title><source>Ann. Intern. Med.</source><year>2023</year><volume>176</volume><fpage>1486</fpage><lpage>1497</lpage><pub-id pub-id-type="doi">10.7326/M23-1394</pub-id><pub-id pub-id-type="pmid">37903369</pub-id>
</element-citation></ref><ref id="B81-idr-17-00056"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Choi</surname><given-names>T.</given-names></name>
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
</person-group><article-title>Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition</article-title><source>JAMA Intern. Med.</source><year>2023</year><volume>183</volume><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2023.0743</pub-id><pub-id pub-id-type="pmid">36951829</pub-id>
</element-citation></ref><ref id="B82-idr-17-00056"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Choi</surname><given-names>T.</given-names></name>
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
</person-group><article-title>Molnupiravir and risk of post-acute sequelae of COVID-19: Cohort study</article-title><source>BMJ</source><year>2023</year><volume>381</volume><fpage>e074572</fpage><pub-id pub-id-type="doi">10.1136/bmj-2022-074572</pub-id><pub-id pub-id-type="pmid">37161995</pub-id>
</element-citation></ref><ref id="B83-idr-17-00056"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomasa-Irriguible</surname><given-names>T.M.</given-names></name>
<name><surname>Monf&#x000e0;</surname><given-names>R.</given-names></name>
<name><surname>Miranda-Jim&#x000e9;nez</surname><given-names>C.</given-names></name>
<name><surname>Morros</surname><given-names>R.</given-names></name>
<name><surname>Robert</surname><given-names>N.</given-names></name>
<name><surname>Bordej&#x000e9;-Laguna</surname><given-names>L.</given-names></name>
<name><surname>Vidal</surname><given-names>S.</given-names></name>
<name><surname>Tor&#x000e1;n-Monserrat</surname><given-names>P.</given-names></name>
<name><surname>Barriocanal</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial</article-title><source>Nutrients</source><year>2024</year><volume>16</volume><elocation-id>1631</elocation-id><pub-id pub-id-type="doi">10.3390/nu16111631</pub-id><pub-id pub-id-type="pmid">38892564</pub-id>
</element-citation></ref><ref id="B84-idr-17-00056"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishna</surname><given-names>B.</given-names></name>
<name><surname>Wills</surname><given-names>M.</given-names></name>
<name><surname>Sithole</surname><given-names>N.</given-names></name>
</person-group><article-title>Long COVID: What is known and what gaps need to be addressed</article-title><source>Br. Med. Bull.</source><year>2023</year><volume>147</volume><fpage>6</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1093/bmb/ldad016</pub-id><pub-id pub-id-type="pmid">37434326</pub-id>
</element-citation></ref><ref id="B85-idr-17-00056"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>D.Y.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Wheeler</surname><given-names>B.</given-names></name>
<name><surname>Young</surname><given-names>H.</given-names></name>
<name><surname>Sunny</surname><given-names>S.K.</given-names></name>
<name><surname>Moore</surname><given-names>Z.</given-names></name>
<name><surname>Zeng</surname><given-names>D.</given-names></name>
</person-group><article-title>Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>1415</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.17876</pub-id><pub-id pub-id-type="pmid">36155617</pub-id>
</element-citation></ref><ref id="B86-idr-17-00056"><label>86.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>US Food and Drug Administration</collab>
</person-group><article-title>First Oral Antiviral for Treatment of COVID-19 in Adults</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults." ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults.</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-07">(accessed on 7 December 2024)</date-in-citation></element-citation></ref><ref id="B87-idr-17-00056"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Su</surname><given-names>B.</given-names></name>
<name><surname>Alcalde-Herraiz</surname><given-names>M.</given-names></name>
<name><surname>Barclay</surname><given-names>N.L.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Wareham</surname><given-names>N.J.</given-names></name>
<name><surname>Paredes</surname><given-names>R.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Prieto-Alhambra</surname><given-names>D.</given-names></name>
</person-group><article-title>Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>6363</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50495-7</pub-id><pub-id pub-id-type="pmid">39075060</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="idr-17-00056-f001"><label>Figure 1</label><caption><p>PRISMA diagram showing selection of studies for review.</p></caption><graphic xlink:href="idr-17-00056-g001" position="float"/></fig><table-wrap position="float" id="idr-17-00056-t001"><object-id pub-id-type="pii">idr-17-00056-t001_Table 1</object-id><label>Table 1</label><caption><p>Impact of COVID-19 vaccine on prevention of long COVID.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Design/Country (Data)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Period/Participants (SARS-CoV-2 Variants)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">LC Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Patient n (F %)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Age (Years), Mean &#x000b1; SD <break/>or Median (IQR)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Vaccinated (%); Vaccine Type and<break/>Vaccination Time</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Vaccine Impact on LC</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ayoubkhani et al. [<xref rid="B44-idr-17-00056" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/UK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Community based;<break/>visit during period of Feb&#x02013;Sep 2021; COVID-19 at least 12 wks before final visit/(A, &#x00394;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 3&#x02013;10 mo after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 28,356 (F 55.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.9 &#x000b1; 13.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated (100%): BNT162b2, mRNA-1273, or ChAdOx1 after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, 1st vaccine 12.8% reduction in odds (<italic toggle="yes">p</italic> &#x0003c; 0.001); 2nd vaccine provided additional 8.8% reduction (<italic toggle="yes">p =</italic> 0.003)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antonelli et al. [<xref rid="B66-idr-17-00056" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective case&#x02013;control study/UK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Community based;<break/>June&#x02013;Nov 2021 (&#x00394;) and Dec 2021&#x02013;Apr 2022 (O)/cases (third dose recipient), controls (second dose recipient) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC Sx &#x02265; 12 wks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All COVID-19, Delta:<break/>n = 1910 in each group (F 57%); Omicron: n = 7894 in each group (F 60.7%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta: cases 64 &#x000b1; 12.8, controls 63.7 &#x000b1; 12.9; Omicron: cases 45.5 &#x000b1; 16.3, controls 44.3 &#x000b1; 17.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated (100%): 3 doses of monovalent in cases, 2 doses in controls) before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No differences between cases and controls in both &#x00394; and O eras, but trend towards protection in vaccinated individuals; when LC, Sx &#x02265; 4 wks, cases with aOR 0.56 (95% CI: 044&#x02013;0.70) during &#x00394; era </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Richard et al. [<xref rid="B67-idr-17-00056" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feb 2020-Dec 2021 (wild-type, A, &#x00394;), data from MHS EPICC study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC Sx &#x02265; 3 mo </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 1832 (F 39%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.5 &#x000b1; 13.7 (age range 18&#x02013;44)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully vaccinated (22.9%) [2 doses of BNT162b2 or mRNA-1273 or 1 dose of Ad26.COV2.S] before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trend towards protective effect, RR 0.73 (95%CI: 0.47&#x02013;1.14) ** <break/>(when LC Sx &#x02265; 28 d, RR 0.72 (0.54&#x02013;0.96)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nehme et al.<break/>[<xref rid="B59-idr-17-00056" ref-type="bibr">59</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective longitudinal cohort/Switzerland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatients, COVID-19 during period of Dec 2021&#x02013;Feb 2022 (O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 3 mo after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 1807 (F 62.3%); COVID-19 negative, n = 882 (F 63.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 positive, 41.6 &#x000b1; 13.5; COVID-19 negative, 43.7 &#x000b1; 14.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully vaccinated (75.5%) [at least 2 doses of mRNA-1273 (61.2%) or BNT162b2 (36.1%)] before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, adjusted prevalence 9.7% vs. 18.1% <italic toggle="yes">(p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brunvoll et al. [<xref rid="B48-idr-17-00056" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort (Norweigian COVID-19 cohort)/Norway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 during period of Nov 2020&#x02013;Oct 2021 (wild-type, A, &#x00394;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 3 mo-15 mo after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 1420 (F 71%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated, 48.3 &#x000b1; 11.4; unvaccinated, 45.7 &#x000b1; 12.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully vaccinated (25%) [at least 2 doses of mRNA vaccines at least 2 wks before COVID-19]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No differences in all components except for memory problem, fully vaccinated vs. unvaccinated, 11.9% vs. 17.3% (<italic toggle="yes">p</italic> = 0.02)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abu Hamdh et al. [<xref rid="B43-idr-17-00056" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/Palestine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 during period of Sep 2021&#x02013; Jan 2022, with FU phone interviews on d 10, 30, 60, 90/(mainly &#x00394;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 90 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 669 (F 57%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.9 &#x000b1; 11.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated (41%) [BNT162b2 (17.8%), Sputnik Light (12.7%), mRNA-1273 (3.7%), Sputnik V (2.4%), ChAdOx1 (2.4%)] before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, &#x02265;1 dose vaccinated vs. unvaccinated, aOR 0.15 (95% CI: 0.09&#x02013;0.24)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatima et al.<break/>[<xref rid="B54-idr-17-00056" ref-type="bibr">54</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/Pakistan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized patients with COVID-19 during period of Feb 2021&#x02013;June 2021/(A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 12 mo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 patients admitted to Aga Khan University hospital, n = 481 (F 38.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.9 &#x000b1; 14.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"># Fully vaccinated (19%): 2 does of vaccines; partially vaccinated (19.2%): 1 dose before COVID-19 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, fully vaccinated aOR 0.38 (95% CI: 0.20&#x02013;0.70), partially vaccinated aOR 0.44 (95% CI: 0.24&#x02013;0.80)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nascimento et al. [<xref rid="B68-idr-17-00056" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/Brazil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized patients with COVID-19 during May 2021 and Feb 2022 (A, &#x00394;, O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 90 d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 patients, n = 412 (35.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 (IQR 48&#x02013;72)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully vaccinated (44.9%) [1 dose of Janssen or 2 doses of # other vaccines before COVID-19] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, aOR for fully vaccinated 0.55 (<italic toggle="yes">p</italic>= 0.007)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catal&#x000e0; et al.<break/>[<xref rid="B49-idr-17-00056" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staggered retrospective cohort /UK (CPRD); Spain (SIDIAP); Estonia (CORIVA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary care data; registered by Jan or Feb 2021, with FU until Jan 2022 (UK), June 2022 (Spain), Dec 2022 (Estonia)/(A, &#x00394;, O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC between 90 d and 365 d after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Over 10 million vaccinated vs. over 10 million unvaccinated (n/a)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated with 1 dose (BNT162b2, ChAdOx1, mRNA-1273, or Ad26.COV2.S) +GOLD (49.7%); * AURUM (49.4); SIDIAP (51.5%); CORIVA (19.4%) before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective: +GOLD, sHR 0.54 (95% CI: 0.44&#x02013;0.67); * AURUM, 0.48 (0.34&#x02013;0.68); SIDIAP, 0.71 (0.55&#x02013;0.91); CORIVA, 0.59 (0.40&#x02013;0.87)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trinh et al.<break/>[<xref rid="B61-idr-17-00056" ref-type="bibr">61</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staggered retrospective cohort/Norway (Norwegian linked health registries)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary care data;<break/>vaccination roll out from Jan to Aug 2021, FU up to 1 yr/(A, &#x00394;, O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC between 90 d and 365 d after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Over 2.3 million vaccinated vs. over 1.5 million unvaccinated (n/a)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated with at least 1 dose (60.7%) [BNT162b2, mRNA-1273, or ChAdOx1] at least 14 d before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, sHR 0.64 (95% CI: 0.55&#x02013;0.74)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Luo et al.<break/>[<xref rid="B57-idr-17-00056" ref-type="bibr">57</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort/Hong Kong</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatient setting; <break/>COVID-19 during period of Dec 2021&#x02013;May 2022/(mainly O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 6&#x02013;12 mo after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 6242 (F 66.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 (IQR 36&#x02013;60)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boosted (57.5%; 3 or more BNT162b2 or CoronaVac) vs. less than 3 doses before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not protective, aOR 1.11 (95% CI: 0.99&#x02013;1.24)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MacCallum-Bridges et al. [<xref rid="B58-idr-17-00056" ref-type="bibr">58</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Population-based retrospective cohort/USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatient setting;<break/>COVID-19 during period of March 2020&#x02013;May 2022/(wild-type, A, &#x00394;, O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 90 d after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 4695 (F 54.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">age 18&#x02013;29 (25.7%); age 30&#x02013;49 (37.6%); age 50&#x02013;64 (24.2%); 65+ (13.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully vaccinated (27.9%) [2 doses of BNT162b2, mRNA-1273, ChAdOx1, or Sinovac or 1 dose of Ad26.COV2.S] before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, aPR 0.42 (95% CI: 0.34&#x02013;0.53)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Babicki et al.<break/>[<xref rid="B45-idr-17-00056" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort/Poland (STOP-COVID registry)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unspecified study period, FU visits at 3 mo and 12 mo after COVID-19/(n/a)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 1 yr after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 801 (F 65.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.5 &#x000b1; 12.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully vaccinated (83%) [2 doses of BNT162b2, mRNA-1273, or ChAdOx1 or 1 dose of Ad26.COV2.S], 73.6% vaccinated after COVID-19, 9.4% before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No differences except headache (17.4% vs. 29.4%, <italic toggle="yes">p</italic> = 0.001), arthralgia (5.4% vs. 10.3%, <italic toggle="yes">p</italic> = 0.032), and dysregulation of HTN (11.6% vs. 18.4%, <italic toggle="yes">p</italic> = 0.030) were more common in unvaccinated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Woldegiorgis et al. [<xref rid="B63-idr-17-00056" ref-type="bibr">63</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional survey/Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 during period of July&#x02013;Aug 2022, FU in 90 d/(O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC at 90 d after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 11,697 (F 52.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">age 18&#x02013;29 (20.9%); age 30&#x02013;39 (21.0%); age 40&#x02013;49 (18.7%); 50&#x02013;59 (18.0%);<break/>60&#x02013;69 (11.6%);<break/>70+ (9.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#Vaccinated, 0&#x02013;2 (6%); 3 doses (76.3%); 4 doses (17.7%) before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, 3 doses aRR 1.3 (95% CI: 1.1&#x02013;1.5); <break/>0&#x02013;2 doses aRR 1.4 (1.2&#x02013;1.8) compared to 4 or more vaccine doses</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xie et al.<break/>[<xref rid="B64-idr-17-00056" ref-type="bibr">64</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional survey/USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatient setting;<break/>2022 National Health Interview Survey/(O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 3 mo or longer post-infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, n = 8757 (weighted 87,509,670) (F 53.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">age 18&#x02013;29 (23.8%); age 30&#x02013;39 (21.3%); age 40&#x02013;49 (18.2%); age 50&#x02013;64 (23.2%); 65+ (13.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"># Vaccinated, 1 dose (17.3%); initial series (33.3%); booster (27.2%) before COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, booster vs. unvaccinated, aOR 0.75 (95% CI: 0.61&#x02013;0.93)</td></tr></tbody></table><table-wrap-foot><fn><p>** Not statistically significant; # vaccine type not specified. Abbreviations; LC, long COVID; n, number; F, female; UK, United Kingdom; USA, United States of America; MHS EPICC, Military Health System Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases With Pandemic; CPRD, Clinical Practice Research Datalink; +GOLD, CPRD GOLD; * ARUM, CPRD ARUM; SIDIAP, Information System for Research in Primary care; FU, follow-up; d, days; wks, weeks; mo, months; yrs, years; n/a, not available; CI, confidence interval; <italic toggle="yes">p</italic>, <italic toggle="yes">p</italic>-value; aOR, adjusted odds ratio; sHR, sub-distribution hazard ratio; aPR, adjusted prevalence ratio; aRR, adjusted risk ratio; HTN, hypertension; Jan, January; Feb, February; Aug, August; Sep, September; Oct, October; Nov, November; Dec, December; A, Alpha; &#x00394;, Delta; O, Omicron.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="idr-17-00056-t002"><object-id pub-id-type="pii">idr-17-00056-t002_Table 2</object-id><label>Table 2</label><caption><p>Impact of antivirals on the prevention of long COVID.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Design/Country </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Period/Participants/(SARS-CoV-2 Variants)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">LC Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Patient n (F %)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Age, Mean &#x000b1; SD or Median (IQR)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Antivirals (Treated %)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Antiviral Impact on LC</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nevalainen et al. [<xref rid="B60-idr-17-00056" ref-type="bibr">60</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized trial/Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized patients with COVID-19 during period of July 2020&#x02013;Jan 2021/(wild type, A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 1 yr after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 114 (F 35.1%); untreated, 94 (F 36.2%).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 57.2 &#x000b1; 13.5; untreated, 59.7 &#x000b1; 13.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir <break/>(200 mg on 1st day, then 100 mg daily for maximum of 10 days) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No differences between remdesivir-treated and untreated with wide CI</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boglione et al. [<xref rid="B78-idr-17-00056" ref-type="bibr">78</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized patients with COVID-19 during period of March 2020&#x02013;Jan 2021(wild type, A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC symptoms &#x02265; 12 wks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total of 449 (F 22%);<break/>Remdesvir-treated, 163; untreated, 165</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65 (IQR 56&#x02013;75.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, OR: 0.64 (95% CI: 0.41&#x02013;0.78)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fern&#x000e1;ndez-de-las-Pe&#x000f1;as et al.<break/>[<xref rid="B55-idr-17-00056" ref-type="bibr">55</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective, case&#x02013;control study/Madrid, Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized patients with COVID-19 during period of Sep 2020&#x02013;March 2021/(wild type, A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 3 mo or later following COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 216 (F 43.5%); untreated, 216 (F 43.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 55.4 &#x000b1; 12.6; untreated, 55.6 &#x000b1; 12.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir<break/>(200 mg on 1st day, then 100 mg daily for maximum of 10 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, OR: 0.401 (95 CI: 0.26&#x02013;0.63)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Durstenfeld et al. [<xref rid="B53-idr-17-00056" ref-type="bibr">53</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated outpatients with their first SARS-CoV-2 positive result between March and Aug 2022/(O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 90 d or later following COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 353 (F 53.3%); untreated, 1258 (F 64.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 62.1 &#x000b1; 12.7; untreated, 55.1 &#x000b1; 13.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nirmatrelvir/ritonavir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No association, aOR: 1.15 (95% CI: 0.80&#x02013;1.64)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang et al. [<xref rid="B62-idr-17-00056" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort/Shanghai, China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Admitted with COVID-19 and then discharged between April and June 2022/(O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 6 mo after being discharged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, 634 (F 54.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.1 &#x000b1; 11.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nirmatrelvir/ritonavir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, OR: 0.35 (95 CI: 0.21&#x02013;0.60)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Congdon et al. [<xref rid="B51-idr-17-00056" ref-type="bibr">51</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort/New York, USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phone interviews between May and Nov 2022; COVID-19 four mo before the phone interview/(O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 4 mo after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 250 (F 66.4%); untreated, 250 (F 73.6%); hospitalized (1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nirmatrelvir/ritonavir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No reduction in overall risk of LC (incidence of 44% vs. 50%, <italic toggle="yes">p</italic> = 0.21; aOR: 0.83, 95% CI: 0.57&#x02013;1.2).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bertuccio et al.<break/>[<xref rid="B46-idr-17-00056" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort/Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatients with mild to moderate COVID-19 during period of April 2021&#x02013;March 2022/(A, 3.5%; &#x00394;, 2.2%; O 94.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 3 mo after COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19, 649 <break/>(F 48.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 (IQR 54&#x02013;76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77 with antivirals (molnupiravir, 41.6%; nirmatrelvir/ritonavir, 13.0%; remdesivir, 45.5%); 141 with mAbs (bamlanivimab/<break/>etesevimab, 44.7%; casirivimab, 16.3%; sotrovimab, 39.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral protective, aOR of 0.43 (95% CI: 0.21&#x02013;0.87) for any symptoms; mAbs protective, aOR of 0.48 (0.25&#x02013;0.92) for neuro-behavioral symptoms</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations; LC, long COVID; n, number; F, female; USA, United States of America; FU, follow-up; d, days; wks, weeks; mo, months; yrs, years; mAbs, monoclonal antibodies; CI, confidence interval; <italic toggle="yes">p</italic>, <italic toggle="yes">p</italic>-value; aOR, adjusted odds ratio; Jan, January; Aug, August; Sep, September; Nov, November; A, Alpha; &#x00394;, Delta; O, Omicron.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="idr-17-00056-t003"><object-id pub-id-type="pii">idr-17-00056-t003_Table 3</object-id><label>Table 3</label><caption><p>Impact of other treatments on prevention of long COVID.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Design/Country (Data)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Study Period/Participants/<break/>(SARS-CoV-2 Variants)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">LC Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Patient n (F %)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Age (Years), <break/>Mean &#x000b1; SD or Median (IQR)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Treatment (Treated %)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Treatment Impact on LC</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gebo et al. [<xref rid="B56-idr-17-00056" ref-type="bibr">56</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized clinical trial/USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatients with COVID-19 between June 2020 and Oct 2021/(wild type, A, &#x00394;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 90 d after CCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">882 (F 57.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 &#x000b1; n/a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No association, aOR: 0.75 (95% CI: 0.46&#x02013;1.23)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yoon et al.<break/>[<xref rid="B65-idr-17-00056" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary analysis of randomized clinical trial/USA (CONTAIN-RCT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized with COVID-19 between April 2020 and March 2021/(wild type, A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 18 mo post-randomization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">281 (F 44.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 (IQR 50&#x02013;67)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No association, aOR: 0.95 (95% CI: 0.54&#x02013;1.67)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bramante et al.<break/>[<xref rid="B47-idr-17-00056" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized clinical trial/USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enrolled from Dec 2020 to Jan 2022/(wild type, A, &#x00394;, O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 10 mo after randomization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1125 (F 56%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (IQR 37&#x02013;54)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"># Metformin, ivermectin, fluvoxamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only metformin was protective; HR: 0.58 (95% CI: 0.38&#x02013;0.88); ivermectin, HR: 0.99 (0.59&#x02013;1.64); fluvoxamine, HR: 1.36 (0.79&#x02013;2.39)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Davelaar et al. [<xref rid="B52-idr-17-00056" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort/Netherlands</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized with COVID-19 between March 2020 and Sep 2021/(wild type, A, &#x00394;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 6 mo after being discharged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123 (F 38.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.1 &#x000b1; 9.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosteroids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective, aOR: 0.32 (95% CI: 0.11&#x02013;0.90)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catal&#x000e1;n et al. [<xref rid="B50-idr-17-00056" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort/Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Telephone survey between March 2021 and April 2021 for patients hospitalized with COVID-19 one yr earlier/(wild type)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC 1 yr after being discharged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76 (F 38%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treated, 68.5 (IQR 60.2&#x02013;75.5); untreated, 61.5 (IQR 52.7&#x02013;72.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosteroids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protective: headache (6.3% vs. 25%, <italic toggle="yes">p =</italic> 0.032); dysphagia (11.4% vs. 0%, <italic toggle="yes">p</italic> = 0.049); depression (22.7% vs. 3.1%, <italic toggle="yes">p</italic> = 0.016), chest pain (11.4% vs. 0%, <italic toggle="yes">p</italic>= 0.049); bodily pain (* SF-36: 100 vs. 75, <italic toggle="yes">p</italic> = 0.017), mental health (* SF-36: 86 vs. 76, <italic toggle="yes">p</italic> = 0.027)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tomasa-Irriguible et al. [<xref rid="B83-idr-17-00056" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized clinical trial/Catalonia, Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outpatients with COVID-19 between Sep 2021 and Feb 2023/(&#x00394;, O)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC after 6 mo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246 (F 68.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.8 &#x000b1; 16.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple micronutrient supplement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No reduction in incidence of LC (intervention, 27.7% vs. placebo, 25%; <italic toggle="yes">p</italic> = 0.785)</td></tr></tbody></table><table-wrap-foot><fn><p># Metformin: a dose of 500 mg on day 1, and then 500 mg twice daily for 4 days, and then 500 mg in the mornings and 1000 mg in the evenings for 14 days; ivermectin: a dose of 390&#x02013;470 mcg/kg/day for 3 days; fluvoxamine: a dose of 50 mg on day 1, and then 50 mg twice daily for 14 days. * SF-36: Short Form-36 quality of life questionnaire. Abbreviations; LC, long COVID; n, number; F, female; USA, United States of America; FU, follow-up; d, days; wks, weeks; mo, months; yr(s), year(s); n/a, not available; CCP, COVID-19 convalescent plasma; CI, confidence interval; <italic toggle="yes">p</italic>, <italic toggle="yes">p</italic>-value; aOR, adjusted odds ratio; HR, hazard ratio; Jan, January; Feb, February; Sep, September; Oct, October; Dec, December; A, Alpha; &#x00394;, Delta; O, Omicron.</p></fn></table-wrap-foot></table-wrap></floats-group></article>